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HEPACAM is a gene encoding a novel immunoglobulin-like cell adhesion 
molecule that is frequently downregulated in human hepatocellular carcinoma 
and several other solid cancers including carcinomas of the breast and colon. 
Re-expression of hepaCAM in several cancer cell lines inhibits proliferation, 
suggesting a putative role as a tumour suppressor. However, the underlying 
mechanisms of hepaCAM-mediated tumour suppression are not understood. 
Expression of hepaCAM, also known as GlialCAM, has been observed in the 
central nervous system and mutations in HEPACAM can give rise to the 
leukodystrophy, megalencephalic leukoencephalopathy with subcortical cysts 
(MLC). In this study, I show a hitherto unknown interaction of hepaCAM with 
the gap junction protein connexin 43 in the human glioblastoma cell line 
U373 MG. Connexin 43, which has an aberrant intracellular localisation in 
U373 MG cells, is re-targeted to the plasma membrane at cellular junctions 
upon hepaCAM expression. Furthermore, hepaCAM expression increases 
connexin 43 protein levels by enhancing its protein stability. Mutations in 
hepaCAM which cause MLC, or neutralisation of hepaCAM with an 
antagonistic antibody disrupt its interaction with connexin 43 at cellular 
junctions. It is proposed that hepaCAM-mediated targeting of connexin 43 to 
cellular junctions increases cell-cell contact and gap junction transfer between 
glioblastoma cells, making it more difficult for them to detach from the 
primary tumour and disseminate during metastasis. I also show in this study 
that proteolytic cleavage of the hepaCAM cytoplasmic domain occurs in 
different human cancer cell lines, and is inhibited by the MLC-causing 
mutations in hepaCAM and the antagonistic hepaCAM antibody. Upon 
 xii 
integrin-mediated adhesion of U373 MG cells to the extracellular matrix 
protein fibronectin, hepaCAM undergoes endocytosis and is concomitantly 
cleaved. The presence of the cleaved hepaCAM fragment in the nucleus 
suggests that it may have functions in regulating gene expression and 
mediating the tumour suppressive activities of hepaCAM. 
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CHAPTER 1 INTRODUCTION 
1.1. Cell adhesion 
Cell adhesion is essential for the assembly of individual cells into three-
dimensional tissues in multicellular organisms. It is both a stable and dynamic 
process. Stable cell adhesion mechanisms maintain tissue structural integrity, 
while dynamic cell adhesion events mediate tissue morphogenesis by 
regulating cellular processes such as growth, migration, differentiation and 
apoptosis (Gumbiner, 1996). 
Cell adhesion is mediated by multi-protein complexes comprising three 
general classes of proteins: cell adhesion molecules (CAMs), the extracellular 
matrix (ECM) proteins, and peripheral membrane proteins (or cytoplasmic 
plaque proteins). CAMs are typically transmembrane glycoproteins that 
mediate diverse cell-cell and cell-ECM interactions at the plasma membrane, 
allowing cells to communicate with one another and with the external 
environment. CAMs on the cell surface are able to bind strongly to ECM 
proteins, most of which are large glycoproteins that assemble into fibrils or 
other structural networks in the extracellular milieu. CAMs also associate with 
peripheral membrane proteins on the intracellular surface of the plasma 
membrane and these interactions serve to connect CAMs to the cytoskeletal 




1.2. Cell adhesion molecules 
The pioneering work on cell adhesion and CAMs began at the turn of the 
twentieth century, and significant progress was made in the identification of 
major CAM families in the late 1970s to 80s (reviewed in Horwitz, 2012). To 
date, hundreds of CAMs have been identified and characterised. Most CAMs 
can be classified into four broad categories: the immunoglobulin-like CAMs 
(Ig-CAMs), cadherins, integrins and selectins. 
1.2.1. Immunoglobulin-like cell adhesion molecules 
Ig-CAMs belong to the immunoglobulin (Ig) superfamily, a large group of 
structurally related proteins which possess one or more Ig-like domains. The 
Ig-like domain is a characteristic sandwich structure made up of two opposing 
anti-parallel beta sheets (Barclay, 2003). Ig-CAMs are calcium (Ca2+)-
independent glycoproteins containing one or more Ig-like loops in their 
extracellular domain, as well as a single transmembrane domain and a 
cytoplasmic tail. Most Ig-CAMs are type I transmembrane proteins, while 
some are linked to the cell surface by a glycosylphosphatidylinositol anchor. 
The cytoplasmic tail of Ig-CAMs is able to interact with cytoskeletal proteins 
such as actin and spectrin, as well as adaptor proteins such as ankyrin 
(Cavallaro and Christofori, 2004; Cavallaro and Dejana, 2011). 
Ig-CAMs establish homophilic trans interactions in which an Ig-CAM on one 
cell binds to the same Ig-CAM type on an adjacent cell. The combination of 
homophilic trans interactions and lateral cis interactions between Ig-CAMs on 
the same cell generate zipper-like structures which stabilise cell-cell adhesion. 
In addition, Ig-CAMs are able to exhibit heterophilic cis and trans interactions 
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with other molecules, including the different members of the Ig-CAM 
superfamily, integrins, cadherins, growth factor receptors and components of 
the ECM. These Ig-CAM mediated intercellular contacts are able to activate 
various proteins involved in signalling pathways, such as receptor tyrosine 
kinases and focal adhesion kinase (FAK) (Cavallaro and Christofori, 2004; 
Cavallaro and Dejana, 2011).  
Ig-CAMs are expressed in diverse cell types throughout the human system 
including epithelial cells, endothelial cells, cells of the nervous system and 
leukocytes. They are implicated in many important cellular processes such as 
tissue morphogenesis, angiogenesis, brain development and immune responses 
(Cavallaro and Christofori, 2004). Some of the well-studied Ig-CAMs include 
NCAM (neural cell adhesion molecule), ICAM-1 (intercellular cell adhesion 
molecule 1), ALCAM (activated leukocyte cell adhesion molecule), VCAM-1 
(vascular cell adhesion molecule 1), PECAM-1 (platelet endothelial cell 
adhesion molecule 1) and the L1 family. 
1.2.2. Integrins 
Integrins are a major family of cell adhesion receptors which mediate cellular 
attachment to the ECM, as well as cell-cell adhesions in vertebrates. Integrins 
are transmembrane heterodimeric glycoproteins consisting of non-covalently 
bound α and β subunits, each of which is a single-pass type I transmembrane 
protein. To date, 18 α and 8 β subunits have been identified in mammals, and 
are known to assemble into 24 distinct heterodimers. The integrin 
heterodimers have different tissue distribution and have been shown to have 
specific and non-redundant functions (Hynes, 2002). 
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The major ligands of integrins are the ECM proteins, including fibronectin, 
laminin, collagen, fibrinogen and vitronectin. In addition to interacting with 
ECM proteins, the extracellular domains of integrins also interact with cell 
surface counter receptors on adjacent cells such as Ig-CAMs, selectins and 
cadherins. The cytoplasmic domains of integrins interact with cytoskeletal 
proteins, providing a transmembrane mechanical link from the extracellular 
contacts to the intracellular cytoskeleton (Calderwood, 2004; Harburger and 
Calderwood, 2009; Hynes, 2002). This large complex of proteins interacting 
with integrins is known as a focal adhesion (Zamir and Geiger, 2001). 
Integrins play important roles in bi-directional signal transduction between the 
extracellular environment and the cell. Integrins mediate “outside-in 
signalling” by binding to their external ligands and transmitting signals into 
the cell, providing information on its location, local environment and adhesive 
state. By activating downstream signalling proteins such as FAK and integrin-
linked kinase (ILK), integrins modulate many aspects of cellular behaviour 
including proliferation, differentiation, survival and migration. Integrins also 
mediate “inside-out signalling” via the cytoplasmic tails to the extracellular 
domains, which then undergo conformational changes and modify their 
affinity to extracellular ligands in a rapid and reversible process known as 
integrin activation. Integrins and their ligands are essential in diverse cellular 
processes including growth, development, immune responses, leukocyte 
traffic and haemostasis (Calderwood, 2004; Harburger and Calderwood, 2009; 




Cadherins are a large superfamily of Ca2+-dependent single-span 
transmembrane proteins involved in diverse processes such as cell-cell 
adhesion, cell polarity, cell sorting during development and tissue 
morphogenesis. Cadherins often engage in homophilic trans interactions in 
which a cadherin molecule binds to the same type of cadherin molecule on 
another cell (Takeichi, 1991). The cadherin superfamily consists of classical 
cadherins and non-classical cadherins. Classical cadherins are primarily 
associated within adherens junctions and are expressed in almost all solid 
tissues. The extracellular domain of classical cadherins contains five cadherin-
type tandem repeats bound together by Ca2+ in a rod-like structure, while the 
cytoplasmic domain binds to the cytoplasmic proteins β-catenin and p120-
catenin, which in turn are linked to α-catenin and the actin cytoskeleton. Of 
the classical cadherins, E-cadherin (epithelial cadherin) is the most commonly 
studied cadherin. Other classical cadherins include N-cadherin (neural 
cadherin) and VE-cadherin (vascular endothelial cadherin) (Gumbiner, 2005; 
Shapiro and Weis, 2009; Takeichi, 1995). Non-classical cadherins include 
desmosomal cadherins which are exclusively expressed in the desmosomes of 
epithelial cells and cardiac muscle cells and are linked to the intermediate 
filament cytoskeleton, as well as protocadherins which are mainly involved in 
neuronal plasticity (Cavallaro and Christofori, 2004; Gumbiner, 2005). 
1.2.4. Selectins 
Selectins are single-chain transmembrane glycoproteins which mediate the 
transient attachment and rolling of leukocytes along the vascular endothelial 
wall during inflammation. Selectins share similar properties to C-type lectins 
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due to the presence of an N-terminal Ca2+-dependent lectin domain in the 
extracellular region which binds sugar moieties. The extracellular region also 
contains an epidermal growth factor-like domain and two to nine short 
consensus repeat units. There are three main types of selectins: P-selectin, 
which is stored within endothelial cells and platelets and is translocated to the 
cell surface within minutes of an inflammatory response to initiate leukocyte 
recruitment to the site of injury; E-selectin, which is expressed on endothelial 
cells in response to inflammatory cytokines and serves to augment leukocyte 
recruitment to the site of injury together with P-selectin; and L-selectin, which 
is expressed on the surface of leukocytes and acts as a homing receptor for 
lymphocytes to enter the peripheral lymph nodes via high endothelial venules 
(Barthel et al., 2007; Tedder et al., 1995). 
1.2.5. Signal transduction of cell adhesion molecules 
While initial studies on CAMs focused on their structural functions in 
mediating adhesion, later research showed that CAMs themselves can act as 
receptors which directly modulate signal transduction by interacting with the 
downstream components of major cellular signalling pathways (Gumbiner, 
1996). The signalling through CAMs can be adhesion-dependent or adhesion-
independent. Adhesion-independent signalling is mediated by the direct or 
indirect interaction of CAMs with growth factor receptors or other signalling 
proteins (Cavallaro and Dejana, 2011). For example, VE-cadherin has been 
shown to interact with vascular endothelial growth factor receptor 2 
(VEGFR2) and prevent activation of the mitogen-activated protein kinase 
(MAPK) pathway, thus inhibiting cell proliferation (Lampugnani et al., 2006). 
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Furthermore, CAMs can undergo cleavage of their extracellular domains by 
proteases such as matrix metalloproteinases (MMPs) and members of the 
ADAM (A Disintegrin And Metalloproteinase) family, thus losing their 
adhesive properties. However, the soluble extracellular domain that is shed 
may still be able to interact with its signalling partners and regulate 
downstream signalling pathways (Cavallaro and Dejana, 2011; van Kilsdonk 
et al., 2010). For example, the ectodomain of L1 is cleaved by ADAM10, and 
the soluble L1 ectodomain shed can bind to the integrin αvβ5, thus facilitating 
the migration of cells on the ECM substrates fibronectin or laminin. As L1 is 
expressed in several human carcinomas, such a mechanism is proposed to 
contribute to metastasis (Mechtersheimer et al., 2001). 
There is also an emerging view that the cytoplasmic domains of CAMs can 
support signal transduction in the absence of their extracellular domains. 
Cleavage of the extracellular domain of CAMs such as cadherins and Ig-
CAMs is frequently accompanied by the release of the cytoplasmic domain 
into the cytosol. Although the biological functions of the resulting cytoplasmic 
fragments are not completely understood, there is some evidence that they 
may mediate signalling responses, as well as translocate to the nucleus and 
regulate gene transcription (Cavallaro and Dejana, 2011). For example, upon 
ectodomain shedding, L1 undergoes further intramembrane processing by 
presenilin/γ-secretase, resulting in the release of a soluble intracellular domain 
which translocates to the nucleus. The cytoplasmic fragment of L1 may 
regulate the transcription of genes such as β3 integrin (Gast et al., 2008; 
Riedle et al., 2009). 
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1.3. Cell-cell adhesion 
Cells make contact with other cells via four distinct junctional complexes: gap 
junctions, tight junctions, adherens junctions and desmosomes. 
1.3.1. Gap junctions 
Gap junctions are cell-cell junctions that directly connect the cytoplasm of two 
contacting cells. The 2-4 nm gap between two cells is bridged by a gap 
junction channel which facilitates the direct transfer of small molecules and 
ions between cells without having to pass through the intercellular space. This 
gap junctional intercellular communication (GJIC) enables cells to exchange 
small metabolites such as ATP and cAMP, second messengers such as Ca2+ 
and IP3, as well as electrical impulses (Laird, 2006; Naus and Laird, 2010; 
Segretain and Falk, 2004).  
Gap junctions are made up of connexins, a family of 21 structurally related 
transmembrane proteins in humans. Connexins have a structure consisting of 
cytoplasmic N- and C-termini, four transmembrane domains, two extracellular 
loops and a cytoplasmic loop (Figure 1). Connexins are assembled in 
hexamers to form a connexon (also known as a hemichannel), and two 
connexons combine to form a gap junction channel. Several gap junction 
channels aggregate together to form a mature gap junction (also known as a 
gap junction plaque). Different types of connexins can combine as homo- or 
hetero-hexamers to form a hemichannel. Furthermore, there is increasing 
evidence that connexin hemichannels can also function as independent entities 
outside of gap junctions to mediate the exchange of small molecules with the 
extracellular milieu (Naus and Laird, 2010; Segretain and Falk, 2004). 
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Figure 1. The structure of connexin 43, the most commonly expressed 
member in the connexin protein family. Connexins are four-pass 
transmembrane proteins with cytoplasmic N-termini (AT) and C-termini (CT), 
two extracellular loops (EL-1 and EL-2) and a cytoplasmic loop (CL). Six 
connexins oligomerise to form a connexon, also known as a hemichannel. 
From Laird (2006). 
 
Most tissues of the body communicate via gap junctions. In excitable tissues 
such as cardiac muscles and the neural network, gap junctions are important 
for the transmission of electrical signals. In non-excitable tissues, gap 
junctions and connexins play key roles in development, tissue homeostasis, 
cell growth control and differentiation (Naus and Laird, 2010). The functions 
of connexins will be discussed in greater detail in section 1.7. 
1.3.2. Tight junctions 
Tight junctions, also known as occluding junctions, form a paracellular barrier 
to regulate the movement of solutes between epithelial or endothelial cells 
(Mitic and Anderson, 1998). They are also important in the establishment and 
maintenance of cell polarity, by restricting the lateral diffusion of lipid and 
protein components between a cell’s apical and basolateral membrane 
domains (Shin et al., 2006). 
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Tight junctions are complex multi-protein structures, of which at least 40 
different protein components have been identified. The major components of 
tight junctions include the transmembrane proteins: claudins, occludins, 
junctional adhesion molecules (JAMs), and the peripheral membrane proteins: 
the zona occludens (ZO) proteins ZO-1, ZO-2 and ZO-3, which are members 
of the membrane-associated guanylate kinase (MAGUK) family (Aijaz et al., 
2006; Mitic and Anderson, 1998; Shin et al., 2006). Claudins play an 
important role in cell-cell adhesion, as well as in regulating tight junction 
selectivity based on the molecular size and ionic charge of solutes (Anderson 
and Van Itallie, 2009). Occludins also mediate cell-cell adhesion (Van Itallie 
and Anderson, 1997), but do not appear to be a critical component of tight 
junctions, as tight junction morphology is not affected in occludin knockout 
mice, although histological abnormalities were observed (Saitou et al., 2000). 
Occludins are linked to the actin cytoskeleton by interaction with the ZO 
proteins, which are scaffold proteins that mediate signal transduction with 
many other interacting partners. These interactions of the ZO proteins are 
important in tight junction assembly (Aijaz et al., 2006; Shin et al., 2006). 
Furthermore, ZO-1 has been reported to interact with adherens junction 
proteins such as α-catenin (Itoh et al., 1997), as well as multiple connexins in 
gap junctions and thus may function in gap junction assembly (Giepmans, 
2004; Rhett et al., 2011).   
1.3.3. Adherens junctions 
Adherens junctions provide strong mechanical attachment between adjacent 
epithelial or endothelial cells and are important in the maintenance of tissue 
integrity. They form an interconnected lateral bridge linking the actin 
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cytoskeleton of neighbouring cells. The key components of adherens junctions 
are cadherins (discussed in section 1.2.3), which are associated with p120 and 
β-catenin or plakoglobin (γ-catenin) via their cytoplasmic domains. The 
association with β-catenin or plakoglobin in turn recruits α-catenin and links 
the protein complex to the actin cytoskeleton. Besides maintaining cell-cell 
adhesion in tissues, adherens junctions also play important roles in tissue 
morphogenesis and remodelling (Meng and Takeichi, 2009; Perez-Moreno et 
al., 2003). 
1.3.4. Desmosomes 
Desmosomes maintain strong adhesion between cells and are linked 
intracellularly to the intermediate filament network. They are important in the 
maintenance of tissue integrity and are particularly abundant in tissues that 
experience mechanical stress, such as the epidermis and myocardium. 
Desmosomes are composed of the desmosomal cadherins, desmocollins and 
desmogleins, which interact with the cytoplasmic proteins plakoglobin and 
plakophilins. Plakoglobin and plakophilins in turn interact with desmoplakin 
and link the desmosomal plaque to intermediate filaments. Desmoplakin 
interacts with keratin intermediate filaments in epithelial cells and desmin 




1.4. Cell-extracellular matrix adhesion 
1.4.1. The extracellular matrix 
The ECM is a complex meshwork of extracellular molecules present in all 
vertebrate tissues and organs and provides structural support to surrounding 
cells, as well as biochemical cues for dynamic cellular processes such as 
growth, differentiation, tissue morphogenesis and wound healing. It is 
composed of proteoglycans, fibrous proteins, water and minerals. The 
proteoglycans found in the ECM can be classified into four main groups: 
hyaluronic acid, chondroitin sulfate, heparan sulfate and keratan sulfate. The 
major fibrous ECM proteins are collagen, elastin, fibronectin and laminin. The 
ECM composition varies in the types and amounts of these molecules, 
depending on the functional requirements of the tissue (Frantz et al., 2010). 
The basement membrane or basal lamina is a specialised ECM underlying all 
epithelial tissues and other cell types such as smooth muscle cells (LeBleu et 
al., 2007). 
The ECM is a dynamic entity that undergoes regulated remodelling in 
response to changes in physiological conditions. Components of the ECM are 
largely produced and organised by fibroblasts. Tissue homeostasis is 
maintained by the controlled secretion of fibroblast MMPs which degrade 
ECM proteins (Mott and Werb, 2004), and is counterbalanced by tissue 
inhibitors of metalloproteinases (TIMPs) (Cruz-Munoz and Khokha, 2008). 
However, this process is often deregulated in cancer, as tumour cells secrete 
MMPs in order to migrate through the basement membrane during metastasis 
(Frantz et al., 2010). 
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Cellular adhesion to the ECM is regulated by integrins (discussed in section 
1.2.2) and can be classified into three major types: focal adhesions, 
hemidesmosomes and dystroglycan complexes. 
1.4.2. Focal adhesions 
Focal adhesions are large dynamic complexes that link the ECM to the actin 
cytoskeleton of the cell. At these sites, integrins are linked to actin via adaptor 
proteins such as vinculin, paxillin, α-actinin and talin and tyrosine kinases 
such as Src and FAK, which regulate the assembly of focal adhesions (Zamir 
and Geiger, 2001). 
1.4.3. Hemidesmosomes 
Hemidesmosomes play a role in the adhesion of epithelial cells to the 
basement membrane in stratified epithelia and other complex epithelia such as 
the skin by connecting the ECM to intermediate filaments such as keratin. A 
hemidesmosomal plaque comprises the transmembrane proteins α6β4 integrin 
and BP180, and the cytoplasmic plaque proteins BP230 and plectin (Borradori 
and Sonnenberg, 1999). 
1.4.4. Dystroglycan complexes 
In skeletal muscles, dystroglycan complexes link the ECM protein laminin to 
the actin cytoskeleton, and are composed of α-dystroglycan, β-dystroglycan 
and the cytoplasmic plaque protein dystrophin. The genetic disease Duchenne 




1.5. Cell adhesion molecules and cancer 
The structural and signalling functions of CAMs are essential in the regulation 
of diverse cellular processes including proliferation, survival, differentiation, 
development, migration, tissue repair, immune responses and inflammation. 
The abundance of CAMs throughout the human body underscores its 
importance in the maintenance of normal physiological activities and tissue 
homeostasis. As such, mutations in CAMs or the unregulated expression of 
CAMs are involved in the pathogenesis of many human diseases. These 
include cancer (Makrilia et al., 2009), neurological diseases such as Charcot-
Marie-Tooth Disease (Kamiguchi et al., 1998), autoimmune diseases such as 
systemic lupus erythematosus and multiple sclerosis (McMurray, 1996), and 
cardiovascular diseases such as coronary artery disease and thrombosis (Hillis 
and Flapan, 1998). In this section, the roles of CAMs in tumourigenesis will 
be further discussed.   
Tumourigenesis is a multi-step process in which the accumulation of genetic 
alterations and other cancer hallmarks cause the progressive transformation of 
normal cells into highly malignant cells (Hanahan and Weinberg, 2000, 2011). 
The aberrant expression of CAMs leads to alterations in cell-cell and cell-
ECM adhesion and underlies several hallmarks in cancer, including invasion, 
metastasis and angiogenesis (Cavallaro and Christofori, 2004; Hanahan and 
Weinberg, 2011; Makrilia et al., 2009). The following sections will discuss a 
few examples of CAMs that are involved in these cancer hallmarks. 
  
 15 
1.5.1. Roles of cell adhesion molecules in the control of cell proliferation, 
survival and death 
Normal cells move from a quiescent state to a proliferative state in response to 
growth-promoting signals. The production and release of growth signals is 
carefully regulated in normal tissues, but deregulated in cancer cells, enabling 
them to be self-sufficient in their growth signals. Cancer cells also acquire the 
ability to evade growth suppression mechanisms and resist cell death 
(Hanahan and Weinberg, 2011). Integrins have been shown to play significant 
roles in the transformation of cells through their ability to promote 
proliferation and inhibit apoptosis (Desgrosellier and Cheresh, 2010; Guo and 
Giancotti, 2004; Makrilia et al., 2009). For example, β4 integrin has been 
shown to promote tumour progression by amplifying HER2 signalling, which 
in turn promotes proliferation and invasion by activation of the transcription 
factors c-Jun and STAT3 (Guo et al., 2006). Integrin signalling via FAK and 
ILK has also been shown to be upregulated in cancer, thus promoting cell 
survival and resistance to apoptosis (Guo and Giancotti, 2004; Hannigan et al., 
2005). The loss of FAK or ILK activity has been shown to promote anoikis, a 
form of apoptosis resulting from the loss of attachment to the ECM (Attwell et 
al., 2000; Duxbury et al., 2004). 
1.5.2. Roles of cell adhesion molecules in invasion and metastasis 
Alterations in CAMs lead to the progression of low-grade benign tumours to 
malignancies of higher pathological grades, as characterised by local invasion 
and distant metastasis. CAMs favouring cytostasis are frequently 
downregulated, and this allows cells to proliferate in an uncontrolled manner, 
as well as to detach and escape from the primary tumour. By inhibiting cell 
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proliferation and migration, these CAMs are conventionally regarded to have 
tumour suppressor functions. A classical example of such a tumour suppressor 
CAM is E-cadherin, which is commonly lost in cancers of epithelial origin. 
E-cadherin is required for the maintenance of adherens junctions with adjacent 
epithelial cells, and its downregulation leads to the loss of cell polarity and a 
more invasive phenotype. The loss of E-cadherin-mediated cell-cell adhesion 
is a rate-limiting step in the progression from adenoma to carcinoma, and an 
inverse correlation has been observed between E-cadherin levels, tumour 
grade and mortality rates. Re-expression of E-cadherin in cancer cells causes 
reversion from an invasive to a benign, epithelial phenotype (Cavallaro and 
Christofori, 2004; Christofori and Semb, 1999; Hanahan and Weinberg, 2011).  
On the other hand, CAMs associated with cell migration are often upregulated 
in invasive carcinomas (Hanahan and Weinberg, 2011). For example, there is 
increasing evidence that the loss of E-cadherin in cancers is accompanied by 
the de novo expression of mesenchymal cadherins such as N-cadherin. This 
cadherin switch during epithelial-mesenchymal transition (EMT) increases the 
invasiveness of tumour cells and enables interaction with endothelial and 
stromal cells, promoting intravasation and metastasis (Cavallaro and 
Christofori, 2004). It has also been reported that Ig-CAMs such as ALCAM, 
L1 and NCAM are upregulated in metastatic cancers, allowing groups of 
cancer cells to retain some cell-cell adhesion as they disseminate from the 
primary tumour and migrate as a unit to distant sites (Wong et al., 2012). 
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1.5.3. Roles of cell adhesion molecules in angiogenesis 
Angiogenesis is an essential step in cancer progression, as tumours are unable 
to grow beyond a limited size unless there is a growth of new blood vessels 
within the tumour. Tumour-associated vasculature not only provides nutrients 
and oxygen to the rapidly proliferating cancer cells, but also enables them to 
gain access to the blood circulation during metastasis. It also enables 
leukocytes to infiltrate the tumour stroma and secrete tumour-promoting 
chemokines and cytokines (Guo and Giancotti, 2004; Hanahan and Weinberg, 
2011). The expression of CAMs such as integrins has been shown to be 
upregulated by vascular endothelial growth factor (VEGF) in tumour 
angiogenesis (Desgrosellier and Cheresh, 2010; Guo and Giancotti, 2004). For 
example, the integrin αvβ3 is not normally expressed in quiescent 
endothelium, but is expressed in angiogenic endothelial cells in tumours. The 
expression of αvβ3 in endothelial cells may facilitate their adhesion to matrix 
proteins deposited in the tumour microenvironment, such as fibronectin, 
fibrinogen and von Willebrand factor. This integrin-mediated adhesion may 
provide survival cues to and promote the migration of invading endothelial 
cells (Brooks et al., 1994; Desgrosellier and Cheresh, 2010). VEGF secretion 
also leads to the upregulation of Ig-CAMs such as ICAM-1, VCAM-1 and 
PECAM-1 in endothelial cells, facilitating their migration (Wong et al., 2012). 
  
 18 
1.6. The HEPACAM gene 
1.6.1. Identification of HEPACAM as a gene suppressed in human 
hepatocellular carcinoma 
HEPACAM was first identified in 2005 as a gene encoding a novel Ig-CAM 
frequently downregulated in hepatocellular carcinoma (HCC) (Moh et al., 
2005a). Its identification was derived from sequence analysis of another gene, 
HEPN1. The novel transcript HEPN1 was identified by suppression 
subtractive hybridisation in a study by Moh et al. (2003) to examine genes 
associated with HCC. HEPN1 was significantly downregulated in 22 out of 23 
HCC patients and in HCC cell lines. Expression of HEPN1 in HepG2 cells 
resulted in reduced cell viability and induced apoptosis. 
 In a subsequent study by Moh et al. (2005a), an updated BLAST search with 
the HEPN1 sequence revealed an uncharacterised and incomplete mRNA 
sequence containing the entire antisense strand of HEPN1 in its 3’ UTR. 
Using the technique of rapid amplification of cDNA ends (RACE), the full-
length sequence was identified from a human normal liver cDNA library and 
later designated as a new gene, HEPACAM. The gene HEPACAM maps to 




Figure 2. Molecular cloning of HEPACAM. An uncharacterised and 
incomplete mRNA sequence of 2465 bp (GenBank accession number: 
AL834419) was retrieved from a BLAST search using the HEPN1 sequence. 
This sequence contained the entire antisense strand of HEPN1 in its 3’-UTR 
and had an incomplete ORF. The full-length cDNA sequence was 
subsequently isolated from a human normal liver cDNA library by RACE and 
later designated as HEPACAM. The gene HEPACAM maps to human 
chromosome 11q24 and contains 7 exons. Adapted from Moh et al. (2005a). 
 
1.6.2. Sequence analysis and structure of the human hepaCAM protein 
Based on sequence analysis, HEPACAM was predicted to encode a novel 
type I transmembrane protein of 416 amino acids. The hepaCAM protein 
displays the typical structure of an Ig-CAM and consists of a signal peptide 
(residues 1-33), an extracellular region (residues 34-240), a transmembrane 
segment (residues 241-261) and a cytoplasmic tail (residues 262-416) (Figure 
3). The extracellular region of hepaCAM comprises two Ig-like domains: a 
V-set domain and a C2-set domain containing a disulfide bond formed 
between two cysteine residues (Moh et al., 2005a). 
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Figure 3. Illustration of the secondary structure of hepaCAM protein. 
Sequence annotation from UniProtKB/Swiss-Prot (accession number: 
Q14CZ8). hepaCAM consists of a signal peptide (SP), an extracellular region 
containing two Ig-like domains (one V-set and one C2-set), a transmembrane 
(TM) segment  and a cytoplasmic tail. 
 
hepaCAM shares structural similarities with JAMs, endothelial cell-selective 
adhesion molecule (ESAM) and coxsackie and adenovirus receptor (CAR), 
which also contain two Ig-like folds (one V-set and one C2-set) in their 
extracellular domains (Moh et al., 2005a). 
The presence of N-glycosylation sites in the hepaCAM extracellular domain 
was predicted by sequence analysis and verified experimentally. A shift in the 
molecular weight of hepaCAM was observed upon enzymatic digestion with 
peptide-N-glycosidase F (PNGase F), which cleaves N-linked glycans. This 
confirmed that hepaCAM is a glycoprotein (Moh et al., 2005a; Moh et al., 
2005b). In a later study by Gaudry et al. (2008), the hepaCAM extracellular 
domain was further shown to be highly glycosylated in two mammalian 
expression systems, HEK and CHO cells, but with significant differences in 
their glycosylation patterns. As glycosylation can influence the activity of 
proteins, hepaCAM expressed in different cell lines may have different 
glycosylation modifications leading to different properties (Gaudry et al., 
2008). 
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Sequence analysis also predicted the presence of multiple potential serine, 
threonine and tyrosine phosphorylation sites in the hepaCAM cytoplasmic 
domain. Moh et al. (2005b) generated a polyclonal antiserum to recognise the 
hepaCAM cytoplasmic domain by immunising rabbits with recombinant 
bacterial fusion protein containing residues 260-416 of hepaCAM. However, 
the rabbit antiserum failed to detect exogenous and endogenous hepaCAM, 
leading the authors to suspect the presence of post-translational modifications 
in the cytoplasmic domain. Upon treatment of the cell lysates with calf 
intestinal alkaline phosphatase, dephosphorylated hepaCAM could be detected 
with the antiserum, confirming that the hepaCAM cytoplasmic domain is 
phosphorylated (Moh et al., 2005b). 
Furthermore, sequence analysis predicted two potential class III PDZ domain-
binding motifs in the cytoplasmic domain of hepaCAM (Moh et al., 2005a), as 
well as putative binding sites for SH3 domains in its proline-rich region (Moh 
et al., 2005b). However, the presence of these motifs in the hepaCAM 
cytoplasmic domain has yet to be verified experimentally. 
1.6.3. Homology of the human hepaCAM protein 
The hepaCAM protein is highly conserved from humans to other organisms 
including mice, rats (Favre-Kontula et al., 2008) and zebrafish (Sirisi et al., 
2014). The human hepaCAM protein is 94% identical to the mouse protein 
and 89% identical to the predicted rat protein (Figure 4). Within the 
extracellular domain of the hepaCAM protein, the conservation between the 




Figure 4. Homology of the human hepaCAM protein to the mouse and rat 
hepaCAM proteins. Multiple sequence alignment of hepaCAM protein 
sequences from human (RefSeq: NP_689935.2), mouse (Mus musculus; 
RefSeq: NP_780398.2) and rat (Rattus norvegicus, predicted; RefSeq: 
XP_002729937.2) was computed with Clustal Omega (EMBL-EBI) and 
visualised with Jalview. Dark grey boxes indicate amino acids conserved in all 
three species, while light grey boxes indicate those conserved in two of the 
three species. The Ig-like domains V-set and C2-set are indicated in red and 
green respectively. The transmembrane (TM) segment is indicated in purple, 
while the cytoplasmic domain is indicated in blue. 
 
1.6.4. Suppression of hepaCAM in human cancers 
The gene HEPACAM was initially identified as being frequently 
downregulated in human HCC. Semi-quantitative RT-PCR showed that 
HEPACAM expression was reduced in 20 out of 23 paired liver tissues of 
HCC patients, and was not detected in five HCC cell lines. Western blot 
analysis confirmed the expression of hepaCAM in normal liver tissues, but not 
in the HCC cell line HepG2 (Moh et al., 2005a). 
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In a subsequent study using the technique of dot blot analysis with a matched 
tumour/normal expression array, the HEPACAM transcript was detected in 
various normal human tissues including breast, colon, kidney, liver and lung 
but was significantly downregulated in tumours of the breast, colon, kidney, 
rectum, stomach and uterus. In addition, HEPACAM mRNA was not detected 
in 11 human cancer cell lines including the breast cancer cell line MCF7 and 
the colon cancer cell lines HCT116, HT29 and Colo205. These data indicated 
that hepaCAM expression is suppressed in diverse human cancers (Moh et al., 
2008). 
1.6.5. Dimerisation of hepaCAM 
Cross-linking experiments in MCF7 cells demonstrated that hepaCAM forms 
homodimers on the cell surface through cis interactions rather than trans 
interactions. Additionally, a deletion mutant of hepaCAM lacking the 
cytoplasmic domain was able to form dimers, indicating that dimerisation is 
independent of the cytoplasmic domain (Moh et al., 2005b). 
1.6.6. Subcellular localisation of hepaCAM 
The subcellular localisation of hepaCAM is dependent on the cell density of 
HepG2 and MCF7 cells (Moh et al., 2005a; Moh et al., 2005b). In well spread 
cells, hepaCAM was localised to punctuate structures in the cytoplasm and 
cell surface protrusions that were about to make contacts with adjacent cells. 
In confluent cell cultures, hepaCAM was predominantly localised on the 
plasma membrane at cell-cell contacts (Moh et al., 2005b). 
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1.6.7. Functional characterisation of hepaCAM in cancer 
1.6.7.1. Effects on cell growth and differentiation 
hepaCAM exerts an inhibitory effect on cell growth in cancer cell lines. 
Exogenous expression of hepaCAM in hepaCAM-negative cell lines HepG2, 
MCF7 and U373 MG (glioblastoma astrocytoma) was demonstrated to inhibit 
proliferation and colony formation (Lee et al., 2009; Moh et al., 2005a; Moh et 
al., 2008). Furthermore, hepaCAM expression in MCF7 cells caused cell cycle 
arrest in the G2/M phase and induced cellular senescence as defined by their 
flat enlarged morphology and increased β-galactosidase activity. This 
hepaCAM-induced senescence in MCF7 cells was shown to be dependent on 
the p53/p21 pathway, as hepaCAM expression led to increased p53, p21 and 
p27 protein levels and reduced cyclin B1 and cdc2 levels. No significant 
effects of hepaCAM expression were observed on cdk4, cyclin D1 and 
cyclin E levels in MCF7 cells (Moh et al., 2008). 
In U373 MG cells, the inhibition of proliferation upon hepaCAM expression 
was also associated with an increase in p21 levels and decrease in cyclin B1 
and D1 levels, although no significant changes in cell cycle progression were 
observed. Interestingly, hepaCAM expression in U373 MG cells also 
significantly increased the expression of glial fibrillary acid protein (GFAP), a 
marker of astrocyte differentiation, and appeared to induce morphological 
changes that were characteristic of astrocytoma differentiation, i.e. from a 
polygonal morphology to a spindle-shaped morphology with long thin 
processes. The degree of differentiation was dependent on the levels of 
hepaCAM. The findings taken together, suggested that hepaCAM is able to 
induce differentiation of U373 MG cells (Lee et al., 2009).  
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In a study by another lab, the mechanism of hepaCAM-mediated tumour 
suppression was investigated in renal cell carcinoma. Consistent with previous 
findings in HepG2 and MCF7 cells, exogenous expression of hepaCAM in the 
renal cell carcinoma cell line 786-0 inhibited cell proliferation. It also caused 
arrest at the G1 phase of the cell cycle, with a concomitant downregulation of 
c-Myc at the post-transcriptional level. Expression of the c-Myc target gene 
and cell cycle protein, p21, was increased, while that of another target gene, 
cyclin D1, was decreased. Subsequent experiments demonstrated that 
hepaCAM expression reduced c-Myc protein stability, which could be rescued 
by treating cells with the proteasomal inhibitor MG132. Additionally, 
hepaCAM expression increased phosphorylation of c-Myc on T58, a signal for 
its ubiquitination. The authors thus concluded that hepaCAM expression 
induces ubiquitin-mediated c-Myc degradation in 786-0 cells, leading to G1 
arrest caused by upregulation of p21 and downregulation of cyclin D1 (Zhang 
et al., 2011). 
hepaCAM mRNA and protein expression was also shown to be downregulated 
in bladder transitional cell carcinoma, compared to adjacent normal tissues 
(Wang et al., 2013; Xu et al., 2012). Overexpression of hepaCAM in bladder 
cancer cell lines inhibited proliferation and this was correlated with a decrease 
in the levels of c-Myc, cyclin D1 and phosphorylated mTOR, and an increase 
in the levels of phosphorylated AMPK. The authors thus suggested that 
hepaCAM may regulate cell proliferation via the AMPK/mTOR pathway 
(Wang et al., 2013).  
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It should be noted however that while the studies by Moh et al. (2008), Zhang 
et al. (2011) and Wang et al. (2013) suggested pathways in which hepaCAM 
inhibits the proliferation of cancer cells, the experimental evidence only 
showed a correlation of hepaCAM expression with changes in the protein 
levels of the pathway mediators. No direct evidence has been provided to 
show that hepaCAM is upstream of or directly influences the signalling 
activities of these pathway proteins. 
1.6.7.2. Effects on cell-ECM interaction 
In the initial characterisation of hepaCAM, the adhesive properties of 
hepaCAM were verified by cell aggregation and spreading assays in HepG2 
cells. Although hepaCAM did not influence cell-cell adhesion, it significantly 
augmented cell-ECM adhesion (Moh et al., 2005a). Expression of hepaCAM 
increased cell adhesion and spreading on the ECM component fibronectin in 
HepG2, MCF7 and U373 MG cells (Lee et al., 2009; Moh et al., 2005a; Moh 
et al., 2005b), and delayed cell detachment in MCF7 cells (Moh et al., 2005b). 
Furthermore, wound healing assays showed that hepaCAM increased cell 
motility in HepG2 and MCF7 cells (Moh et al., 2005a; Moh et al., 2005b). 
Expression of hepaCAM also increased the invasiveness of HepG2 cells as 
shown by the transwell Matrigel invasion assay (Moh et al., 2005a), although 
this was not observed in MCF7 cells due to their poorly invasive nature (Moh 
et al., 2005b). Intriguingly, in U373 MG cells, hepaCAM expression inhibited 
cell motility and invasion, indicating that hepaCAM may signal differently in 
different cell types (Lee et al., 2009), possibly due to different protein 
interactions or post-translational modifications.  
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1.6.7.3. Effects on vascular endothelial growth factor expression 
Semi-quantitative RT-PCR showed that compared to adjacent normal tissues, 
HEPACAM mRNA expression was reduced in urothelial carcinoma tissues, 
and this was correlated with a significant increase in VEGF mRNA 
expression. In vitro experiments in 786-0 cells and the bladder carcinoma cell 
line T24 demonstrated that transfection of the HEPACAM gene was correlated 
with a significant decrease in VEGF protein levels (Yang et al., 2010; Zhang 
et al., 2013). In a subsequent study, human umbilical vein endothelial cells 
(HUVECs) treated with 786-0 cell-derived exosomes showed increased tube 
formation, which was correlated with increased VEGF expression in HUVECs 
and reduced hepaCAM expression (Zhang et al., 2013). 
1.6.7.4. hepaCAM as a putative tumour suppressor  
In summary, the frequent loss of HEPACAM in human HCC and the anti-
proliferative effects of hepaCAM fulfil two important criteria as a tumour 
suppressor, as suggested by Moh et al. (2005a). Subsequent studies (Moh et 
al., 2008) also showed that hepaCAM expression is downregulated in diverse 
human cancers, further supporting that hepaCAM is a putative tumour 
suppressor. 
1.6.8. The cytoplasmic domain of hepaCAM and its proteolytic cleavage 
As mentioned in section 1.6.2, the cytoplasmic domain of hepaCAM is 
phosphorylated, suggesting that it may play a role in signalling cascades 
regulating cell adhesion and migration. To examine the importance of the 
cytoplasmic domain in the biological functions of hepaCAM, Moh et al. 
(2005b) constructed hCAM-tailless, a deletion mutant of hepaCAM lacking 
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the cytoplasmic domain (residues 264-416). MCF7 cells expressing hCAM-
tailless displayed rates of wound healing comparable to mock-transfected 
cells, indicating that the hepaCAM cytoplasmic domain is essential for the 
functions of hepaCAM in cell motility. Deletion of the hepaCAM cytoplasmic 
domain also resulted in reduced cell adhesion to fibronectin, suggesting that 
the hepaCAM cytoplasmic domain is also important in mediating cell 
adhesion (Moh et al., 2009b; Moh et al., 2005b). 
Moh et al. (2008) also showed that deletion of the cytoplasmic domain 
inhibited the tumour suppressor functions of hepaCAM. While expression of 
wild-type hepaCAM strongly inhibited proliferation and colony formation in 
MCF7 cells, expression of hCAM-tailless only resulted in a moderate 
inhibition. Unlike wild-type hepaCAM, the hCAM-tailless mutant also failed 
to cause cell cycle arrest in the G2/M phase and induce cellular senescence via 
the p53/p21 pathway. This suggests that growth inhibition and cell cycle 
regulation by hepaCAM are mediated by its cytoplasmic domain (Moh et al., 
2008).  
A later study by Zhang et al. (2010a) showed that hepaCAM undergoes 
proteolytic cleavage when exogenously expressed in MCF7 cells, generating a 
25 kD fragment that consists mainly the cytoplasmic domain. To identify the 
molecular mechanisms of hepaCAM cleavage, the authors studied several 
signalling pathways known in regulating the cleavage of CAMs. Treatment 
with the phorbol ester PMA did not affect hepaCAM cleavage, while calcium 
influx promoted hepaCAM cleavage independent of the protein kinase C 
(PKC) pathway. On the other hand, treatment with the proteasome inhibitor 
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MG132, as well as with inhibitors of the cysteine proteases calpain-1 and 
cathepsin-B reduced hepaCAM cleavage. This suggested the possible 
involvement of the proteasome, calpain-1 and cathepsin-B in proteolytic 
cleavage of the hepaCAM cytoplasmic domain, and it is speculated that this 
may serve a regulatory role in the functions of hepaCAM in response to 
various cellular signals (Zhang et al., 2010a). 
1.6.9. Identification of HEPACAM in the nervous system 
HEPACAM was also identified and cloned in independent studies by other 
labs. In a study by Spiegel et al. (2006) to identify novel molecules expressed 
in peripheral myelinated nerves, HEPACAM was identified in cDNA libraries 
prepared from primary rat Schwann cells and rat sciatic nerves. Separately, 
using a structure-based genome-mining approach targeting VEGF and platelet 
derived growth factor (PDGF) Ig-like folds, Favre-Kontula et al. (2008) 
identified a sequence corresponding to a single-pass transmembrane protein 
containing two Ig-like domains. This sequence was cloned by exon assembly 
from a human brain genomic library and found to be identical to HEPACAM.  
1.6.10. Role of HEPACAM in the nervous system 
In addition to its function as a tumour suppressor gene in HCC and other 
human cancers, HEPACAM plays important roles in the central nervous 
system (CNS). In the study by Favre-Kontula et al. (2008), the hepaCAM 
protein was observed to be highly expressed in the human and mouse CNS, 
and was thus also named as GlialCAM. Its expression was upregulated during 
postnatal mouse brain development, in a coordinate manner with myelin basic 
protein. hepaCAM was also expressed in primary rat oligodendrocytes at 
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various stages of differentiation, where they could be detected in the cell body 
and cell processes, suggesting a potential role of hepaCAM in myelination and 
oligodendrocyte biology. Furthermore, hepaCAM expression was observed in 
primary rat astrocytes at the tip of cell processes in low-density cultures, and 
at cell-cell contact sites in confluent cultures, suggesting a role of hepaCAM 
in astrocyte-astrocyte interactions (Favre-Kontula et al., 2008). 
1.6.11. Role of HEPACAM in the disease megalencephalic 
leukoencephalopathy with subcortical cysts 
HEPACAM is the second gene involved in the hereditary disease 
megalencephalic leukoencephalopathy with subcortical cysts (MLC). MLC is 
a rare type of leukodystrophy and the classical phenotype is characterised by 
infantile-onset macrocephaly and delayed-onset neurological deterioration. 
Recessive mutations in the gene MLC1 are observed in 75% of MLC patients. 
In identifying another MLC-related gene, hepaCAM was found to be a direct 
interacting partner of MLC1, a membrane protein with putative roles in ion 
transport. Subsequent genetic analysis of patients without MLC1 mutations 
revealed that a large proportion had mutations in HEPACAM instead. Several 
different HEPACAM mutations were identified, and these mutations could be 
dominant or recessive (Lopez-Hernandez et al., 2011a). Mutations in 
HEPACAM and MLC1 are believed to prevent proper ion and water 
homoeostasis of the brain, thus leading to a defect in brain volume regulation 
and chronic white matter oedema (van der Knaap et al., 2012). 
Further molecular studies showed that hepaCAM interacts and co-localises 
with MLC1 in cell-cell junctions between astrocytes. Expression of hepaCAM 
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mutations in astrocytes and HeLa cells resulted in a diffused intracellular 
localisation of both hepaCAM and MLC1 with some enrichment in plasma 
membranes but not specifically at cell-cell junctions. This suggested that 
hepaCAM is required for the proper targeting of MLC1 to cell-cell junctions, 
and mutations in hepaCAM cause a mislocalisation of both molecules (Lopez-
Hernandez et al., 2011a; Lopez-Hernandez et al., 2011b). These cell-cell 
junctions in which MLC1 was localised to were shown in another study to 
contain components typically found in tight junctions (occludin and ZO-1), 
adherens junctions (β-catenin) and gap junctions (connexin 43) (Duarri et al., 
2011). 
A later study identified hepaCAM as a binding partner of the chloride channel 
ClC-2 and showed that the two proteins co-localised in cell-cell junctions 
between astrocytes. hepaCAM also targets ClC-2 to these junctions and 
modifies ClC-2-mediated currents in vitro (Hoegg-Beiler et al., 2014; 
Jeworutzki et al., 2012). 
1.6.12. Interactions of hepaCAM with other proteins 
1.6.12.1. Actin 
hepaCAM has been shown to associate with the actin cytoskeleton. hepaCAM 
co-localised with F-actin predominantly at the cell-cell contacts of MCF7 
cells, and the subcellular localisation of hepaCAM was dependent on the 
integrity of the actin cytoskeleton. A direct interaction between hepaCAM and 
F-actin was verified by co-immunoprecipitation and co-sedimentation assays. 
Deletion of the first or second Ig-like domains or the cytoplasmic domain of 
hepaCAM resulted in a loss of interaction, indicating that an intact hepaCAM 
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is required for its stable interaction with the actin cytoskeleton. This 
interaction is suggested to be important for the functions of hepaCAM in 
mediating cell adhesion and migration (Moh et al., 2009b). 
1.6.12.2. Caveolin-1 
hepaCAM also associates with caveolin-1, a principal structural component of 
caveolae which are plasma membrane invaginations and a specialised type of 
lipid rafts. hepaCAM was shown to co-localise with caveolin-1 in the nucleus 
and punctuate structures in the cytoplasm. The two proteins could be co-
immunoprecipitated and the association was shown to be dependent on the 
first Ig-like domain of hepaCAM. Since caveolae and caveolin-1 are involved 
in endocytosis and signal transduction, it is suggested that the association of 
hepaCAM with caveolin-1 may play a role in the signalling processes of 
hepaCAM. Furthermore, as caveolin-1 is downregulated in several cancers 
and has also been proposed to function as a tumour suppressor, its association 
with hepaCAM may contribute to the tumour suppressive activities of 
hepaCAM (Moh et al., 2009a). 
1.7. Connexin 43 and other connexins 
As discussed in section 1.3.1, connexins are the major components of gap 
junctions. In this section, the synthesis and turnover of connexins, as well as 
the functions of connexins in tumourigenesis will be discussed further with an 
emphasis on connexin 43, which is of particular interest to this project.  
Connexins are named according to their molecular weights. Connexin 43, 
encoded by the gene GJA1 with a molecular weight of 43 kD, is the most 
ubiquitously expressed of the 21 human connexins. Found in almost all organ 
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systems, it is expressed in a broad spectrum of cell types including astrocytes, 
cardiomyocytes, keratinocytes and smooth muscle cells (Laird, 2006). Due to 
the diverse expression pattern of connexin 43, alterations in connexin 43 gap 
junction communication are associated with many pathologies including 
ischemic heart disease (Smith et al., 1991), the pleiotropic development 
disorder oculodentodigital dysplasia (Paznekas et al., 2003) and cancer 
(Cronier et al., 2009; Mesnil et al., 2005; Naus and Laird, 2010). 
1.7.1. The life cycle of connexins 
Similar to other transmembrane proteins, connexins are synthesised by 
endoplasmic reticulum (ER)-bound ribosomes and inserted co-translationally 
into the ER membrane. Oligomerisation of connexins into connexons occurs 
during their transport between the ER and the trans-Golgi network. Upon the 
completion of oligomerisation, connexons are packaged into vesicles and 
trafficked to the plasma membrane, where they can dock with connexons on 
adjacent cells to form gap junction channels which coalesce with other 
channels to form a gap junction plaque. Alternatively, connexons may remain 
undocked and function as hemichannels (Laird, 2006; Segretain and Falk, 
2004).  
Connexin proteins have a short half-life of only a few hours, which is 
surprisingly short for a structural membrane protein. Gap junction turnover 
has been widely shown to occur within several hours of their delivery to the 
cell surface, and involves the internalisation of gap junctions into annular 
junctions (also known as connexosomes). These gap junction complexes are 
subsequently disassembled and individual connexin proteins are targeted for 
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degradation in lysosomes, or an alternative pathway involving the proteasome 
(Berthoud et al., 2004; Laird, 2006; Segretain and Falk, 2004). The synthesis 
and degradation of connexins, in particular connexin 43, is summarised in 
Figure 5 below. 
 
Figure 5. An overview of the life cycle of connexin 43. Connexin 43 
undergoes a continuous renewal process in cells. From Naus and Laird (2010). 
 
Though not well-understood, the continuous synthesis and turnover of 
connexins is believed to be another mechanism to regulate GJIC, in addition to 
the opening and closing of gap junction channels. This may facilitate the rapid 
up- or down-regulation of gap junction activity based on the physiological 
requirements of cells (Segretain and Falk, 2004). 
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1.7.2. Post-translational modification of connexins 
Connexins undergo different types of post-translational modifications, 
including phosphorylation, hydroxylation, acetylation and palmitoylation. 
These modifications can regulate the functions of connexins in and outside of 
gap junctions, as well as the assembly and turnover of gap junctions. The most 
studied of these post-translational modifications is phosphorylation, which can 
occur on various residues on the cytoplasmic loop or C-terminal domain of 
connexins. Phosphorylation of connexins by kinases such as Src, PKC and 
MAPKs has been observed in at least nine connexins, including connexin 43. 
In the case of connexin 43, phosphorylation on different residues can either 
enhance or inhibit GJIC, as well as influence its functions independent of gap 
junctions (Dbouk et al., 2009; Solan and Lampe, 2009). 
1.7.3. Role of connexins in tumourigenesis 
1.7.3.1. Connexins as tumour suppressors 
The role of gap junctions and connexins in tumorigenesis was first suggested 
by Loewenstein and Kanno (1966), when a lack of electrical coupling was 
observed in rat hepatomas. Since then, there has been a multitude of studies 
exploring the link between connexins and cancer. Firstly, it was observed that 
gap junctions and connexins are frequently downregulated or completely lost 
in human or rodent solid tumours, as well as in cell lines derived from various 
tumour types (Huang et al., 1998; Laird et al., 1999; Mesnil et al., 2005; Tsai 
et al., 1996). In several studies, an aberrant localisation of connexins in 
transformed cells has also been reported in vivo and in vitro, instead of a 
downregulation in connexin expression. While connexins are usually localised 
on the plasma membrane at cell-cell contacts, a cytoplasmic localisation of 
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connexins has been observed in transformed cells (Mesnil et al., 2005), 
including glioblastoma cells (Cottin et al., 2008; Cottin et al., 2011). 
Secondly, the re-introduction of connexin expression in transformed cells 
inhibits cell proliferation and tumour growth (Eghbali et al., 1991; Huang et 
al., 1998). Connexin overexpression also causes partial re-differentiation of 
transformed cells and inhibits angiogenic processes (Hirschi et al., 1996; 
McLachlan et al., 2006). 
Thirdly, the involvement of connexins in tumour suppression is also supported 
by studies involving the knockdown or knockout of connexins. Silencing of 
connexins has been reported to promote tumour cell growth and migration 
(Shao et al., 2005). In studies using connexin knockout (King and Lampe, 
2004a, b; Temme et al., 1997) and heterozygous mice (Avanzo et al., 2004), as 
well as transgenic mice expressing dominant-negative mutants of connexins 
(Dagli et al., 2004), an increase in tumour incidence was observed upon 
exposure of the mice to carcinogens. The experimental evidence thus pointed 
to a role for the loss of connexin expression in tumourigenesis. 
The tumour suppressive properties of connexins have been proposed to be 
GJIC-dependent, as well as GJIC-independent by interaction with other 
tumour suppressor molecules (reviewed in Cronier et al., 2009; Mesnil et al., 
2005; Naus and Laird, 2010). 
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1.7.3.2. GJIC-dependent mechanisms of connexin-mediated tumour 
suppression 
The loss of GJIC in tumourigenesis can be attributed to the loss of expression 
or aberrant localisation of connexins, resulting in the lack of functional gap 
junctions between cells. It is believed that the loss of GJIC between 
neighbouring cells facilitates cell dissociation in the invasive regions of the 
primary tumour (Mesnil et al., 2005). It has been proposed that the tumour 
suppressive roles of connexins are linked to GJIC-mediated homeostatic 
exchange of small molecules in normal healthy tissues (Naus and Laird, 
2010). However, the nature of the molecules that need to be exchanged to 
prevent cells from transforming to a more invasive phenotype is not well-
characterised. One of the molecules exchanged via GJIC is glutathione 
(Goldberg et al., 1999), and it has been suggested that the antioxidant 
properties of glutathione protect cells from reactive oxygen species, and thus 
DNA damage in the tumorigenic process (Naus and Laird, 2010). 
The GJIC-mediated exchange of small molecules has also been explored as a 
mechanism of the “bystander effect” in cancer therapy. The bystander effect is 
a phenomenon in which the effects of a therapeutic agent are spread from the 
targeted cells to neighbouring non-targeted cells in a tumour mass, thereby 
achieving maximal killing of cancer cells (Prise and O'Sullivan, 2009). For 
example, a strategy that has been studied is the transfer of the toxic 
metabolites of the prodrug ganciclovir from targeted tumour cells to 
surrounding non-targeted cells via GJIC (Mesnil and Yamasaki, 2000). 
 38 
1.7.3.3. GJIC-independent mechanisms of connexin-mediated tumour 
suppression 
In addition to their roles in gap junctions and hemichannels, connexins are 
involved in various functions mediated by their interacting partners. These 
interactions lead to the modulation of gene expression in several processes 
including cell proliferation, cell migration and angiogenesis (Dbouk et al., 
2009; Naus and Laird, 2010). 
The re-introduction of connexins in cancer cell lines inhibits proliferation by 
regulating the expression of genes involved in the cell cycle. Overexpression 
of connexin 43 has been correlated with decreased expression of cyclin A, 
cyclin D1, cyclin D2, and various cyclin-dependent kinases (CDKs) (Chen et 
al., 1995). Connexin 43 also increases the levels of the CDK inhibitors p21 
and p27 and inhibited cell cycle progression from G1 to S phase (Sanchez-
Alvarez et al., 2006; Zhang et al., 2001). 
In addition, connexin 43 has been shown to regulate the expression of 
molecules involved in angiogenesis. Silencing of connexin 43 downregulates 
the expression of the anti-angiogenic factor TSP-1 and upregulates the 
expression of the pro-angiogenic factor VEGF (Shao et al., 2005). In another 
study, connexin 43 overexpression results in decreased endothelial cell 
tubulogenesis and migration in vitro, and reduced blood vessel formation in 
xenoplant tumours, without re-establishing GJIC (McLachlan et al., 2006). 
Connexin 43 has also been reported to interact with the tumour suppressor 
caveolin-1 in the lipid rafts of keratinocytes (Langlois et al., 2008), and this 
interaction is altered in keratinocyte transformation processes in vitro, 
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suggesting a role for this interaction in tumour suppression (Langlois et al., 
2010). In a caveolin-1 positive keratinocyte cell line, connexin 43 knockdown 
leads to EMT features and increased cell invasion, while connexin 43 
overexpression protects against the stimulation of cell invasion in a GJIC-
independent mechanism (Langlois et al., 2010). 
The interaction of connexin 43 with the matricellular protein NOV (CCN3) 
has also been documented as another GJIC-independent tumour suppression 
mechanism. Exogenous expression of connexin 43 in glioma and 
choriocarcinoma cells leads to an upregulation of NOV expression and a 
physical interaction of these two proteins is observed As NOV has been 
shown to inhibit cell proliferation and suppress tumourigenesis, it is suggested 
to be a putative downstream effector of connexin 43-mediated signalling 
cascades (Fu et al., 2004; Gellhaus et al., 2004; Gupta et al., 2001).  
1.7.3.4. Connexins and metastasis 
While the above sections have focused on the tumour suppressive roles of 
connexins, there is increasing evidence that connexins may instead facilitate 
invasion and metastasis. Connexin 43 expression has been shown to enhance 
the transendothelial migration or diapedesis of breast tumour cells. This 
suggested that the establishment of heterocellular GJIC between tumour cells 
and endothelial cells may be a key regulatory step during metastasis 
(Pollmann et al., 2005). Similarly, connexin 26 was proposed to facilitate the 
intravasation and extravasation of melanoma cells through heterologous gap 
junction formation with endothelial cells (Ito et al., 2000). 
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Furthermore, the formation of heterotypic gap junctions between a human 
breast carcinoma cell line and a human osteoblastic cell line was proposed as 
an explanation for the preferential metastasis of breast cancer cells to bones 
(Kapoor et al., 2004). Although there are limited studies on this aspect, the 
establishment of heterotypic GJIC between metastatic cells and cells of the 
colonised tissue may play an important role in metastasis (Cronier et al., 2009; 
Mesnil et al., 2005).  
In summary, the seemingly contradictory roles of connexins in tumourigenesis 
may depend on the type of connexin being expressed and the cell or tumour 
type. Connexins may thus be better classified as conditional tumour 
suppressors due to their complex roles in mediating tumour suppression and 
progression (Mesnil et al., 2005; Naus and Laird, 2010). 
1.8. Objectives of the project 
1.8.1. Current perspectives and aims of the project 
hepaCAM is a novel Ig-CAM and putative tumour suppressor. Several studies 
(discussed in section 1.6.7.1) have shown a correlation of hepaCAM 
expression with changes in the protein levels of genes involved in regulating 
proliferation and the cell cycle. However, no direct evidence has been 
provided to show that hepaCAM interacts with and has a direct influence on 
the signalling activities of these regulatory proteins. Thus, the underlying 
mechanisms of hepaCAM-mediated tumour suppression are still not 
completely understood. 
As discussed in section 1.6.11, in a separate area of research in neurobiology, 
hepaCAM has recently been shown to interact with MLC1, and MLC1 in turn 
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partially co-localises with the gap junction protein connexin 43 in astrocytic 
cell-cell junctions. Since connexin 43 has also been identified as a tumour 
suppressor protein, we hypothesise that hepaCAM may exert its tumour 
suppressive effects by influencing the activities of connexin 43. Thus, the first 
aim of this project is to characterise the interaction of hepaCAM with 
connexin 43 in cancer cells and understand whether this interaction 
contributes to hepaCAM’s tumour suppressor activities. 
In addition, as discussed in section 1.6.8, hepaCAM undergoes proteolytic 
cleavage in breast cancer cells to generate a 25 kD fragment containing mainly 
the cytoplasmic domain. However, the cellular signals which lead to 
hepaCAM cleavage and its biological significance have yet to be elucidated. 
As it has been proposed that the cytoplasmic domain of CAMs may support 
signalling in the absence of the extracellular domain (discussed in section 
1.2.5), we hypothesise that proteolytic cleavage of the hepaCAM cytoplasmic 
domain occurs as part of its processing and signalling activities. Thus, the 
second aim of this project is to understand the upstream signals which lead to 
hepaCAM cytoplasmic domain cleavage, and investigate its functional 
significance in cancer cells. 
1.8.2. Project approaches 
To the first aim of the project, the human glioblastoma cell line U373 MG of 
astrocytic origin will be used. The U373 MG cell line does not endogenously 
express hepaCAM and our lab has established stable transfections of 
U373 MG cells expressing wild-type (WT) hepaCAM, as well as the empty 
vector as a control. In the initial stages of the project, I demonstrate that 
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U373 MG cells has an aberrant localisation of connexin 43 in the cytoplasm 
similar to previous reports in other glioblastoma cell lines, and that exogenous 
hepaCAM expression in U373 MG cells causes a re-localisation of 
connexin 43 to cell-cell junctions. To further characterise the relationship of 
hepaCAM with connexin 43, I will also utilise stable U373 MG cell lines 
established in our lab which express mutations of hepaCAM involved in the 
disease MLC. 
In the second part of the project, the proteolytic cleavage of the hepaCAM 
cytoplasmic domain will be studied in U373 MG cells, the human breast 
adenocarcinoma cell line MCF7 and the human HCC cell line HepG2. MCF7 
and HepG2 cells stably transfected with hepaCAM have been established 
previously and will be used in the project, along with the corresponding 
parental or vector-transfected cells. The stable U373 MG cells expressing WT 
and mutant hepaCAM will also be used in this part of the project to investigate 
whether mutations in hepaCAM have any effects on its proteolytic cleavage. 
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CHAPTER 2 MATERIALS AND METHODS 
2.1. Cell culture 
2.1.1. Cell lines and culture conditions 
The human glioblastoma astrocytoma U373 MG cell line was a kind gift from 
Associate Professor Celestial Yap from the Department of Physiology, NUS. 
Cells were cultured in F-12 medium (Life Technologies, Carlsbad, CA, USA) 
supplemented with 10% fetal bovine serum (FBS; Biowest, Nuaille, France). 
The human embryonic kidney 293 cell line containing the SV40 large T 
antigen (HEK293T) was a kind gift from Associate Professor Paul MacAry 
from the Department of Microbiology, NUS. Cells were cultured in high 
glucose Dulbecco’s Modified Eagle Medium (DMEM; Sigma-Aldrich, St. 
Louis, MO, USA) supplemented with 10% FBS. 
The human breast adenocarcinoma cell line MCF7 and the human 
hepatocellular carcinoma cell line HepG2 were cultured in high glucose 
DMEM supplemented with 10% FBS. 
All cells were grown at 37°C in a humidified incubator supplied with 5% CO2. 
2.1.2. Subculture of adherent cells 
Cells were maintained in the log phase and passaged when they reached 80-
100% confluence. The culture medium was aspirated and cells were rinsed 
once with phosphate-buffered saline (PBS). Cells were incubated with 1× 
trypsin-EDTA (Biowest) for 2-5 min at 37°C until they were detached. 
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Subsequently, cells were resuspended in fresh medium to inactivate trypsin 
and split 1:4 or to the required cell density. 
2.1.3. Cryopreservation of cells 
Cells were detached and spun down at 200 × g for 5 min. The cell pellet was 
resuspended in freezing medium (consisting of culture medium with 10% FBS 
and 8% DMSO) to a minimum density of 1 × 106 cells/ ml. The cell 
suspension was transferred to a cryotube and stored at -80°C overnight, before 
transferring to liquid nitrogen for long term storage. 
2.2. DNA constructs 
The plasmids used for the transfection of U373 MG and HEK293T cells, 
GlialCAM-WT-3.1, GlialCAM-R92Q-3.1, GlialCAM-R92W-3.1 and the 
corresponding empty vector pcDNA3.1 were provided by Professor Raúl 
Estévez, University of Barcelona, Spain. WT hepaCAM (GlialCAM), 
hepaCAM-R92Q and hepaCAM-R92W were cloned into the pcDNA3.1 
vector with a C-terminal 3×FLAG epitope (Lopez-Hernandez et al., 2011a). 
The plasmids used for the transfection of MCF7 and HepG2 cells, hepaCAM-
pcDNA6B/His and the corresponding empty vector pcDNA6B/His were 
provided by Dr Moh Mei Chung, NUS. hepaCAM was cloned into the 
pcDNA6B/V5-His vector with a C-terminal V5 epitope and poly-histidine tag 
(Moh et al., 2005a). 
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2.3. Transformation of Escherichia coli 
50-100 ng of plasmid DNA was mixed with 20-50 μl of competent E. coli 
DH5α cells (New England Biolabs, Ipswich, MA, USA) and incubated on ice 
for 30 min. The cells were then subjected to heat-shock at 42°C for 30 seconds 
and immediately cooled on ice for 2 min. 1 ml of Luria-Bertani (LB) broth 
was added to the cells and incubated at 37°C for 1 hour with shaking. After 
incubation, the cells were pelleted by centrifugation at 3,000 rpm for 3 min. 
The transformation mixtures were subsequently plated onto LB agar plates 
containing the appropriate antibiotic and incubated overnight at 37°C. 
2.4. Plasmid miniprep 
A single E. coli colony was inoculated into 5 ml LB broth supplemented with 
the appropriate antibiotic and incubated overnight at 37°C with shaking. 
Plasmid DNA was purified from the E. coli culture using the Wizard Plus SV 
Minipreps DNA Purification System (Promega, Madison, WI, USA), 
according to the manufacturer’s instructions. Using this kit based on the 
alkaline lysis method, the E. coli culture was pelleted by centrifugation at 
13,000 rpm for 1 min and the pellet was resuspended completely in 250 μl 
Cell Resuspension Solution. Thereafter, E. coli cells were lysed in 250 μl Cell 
Lysis Solution. The lysate was incubated with 10 μl Alkaline Protease 
Solution for 5 min at room temperature to inactivate endonucleases and other 
proteins released during lysis which may affect the quality of the plasmid 
DNA. Subsequently, the lysate was mixed with 350 μl Neutralisation Solution 
and spun down at 13,000 rpm for 10 min to precipitate unwanted cellular 
debris containing chromosomal DNA and proteins. The cleared lysate 
containing the plasmid DNA was transferred to a spin column and centrifuged 
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at 13,000 rpm for 1 min. The immobilised DNA was washed with 750 μl and 
subsequently 250 μl of Column Wash Solution. Finally, the DNA was eluted 
with sterile nuclease-free water and the concentration was quantified using the 
NanoDrop spectrophotometer (Thermo Scientific, Rockford, IL, USA). The 
plasmid DNA was stored at -20°C until use. 
2.5. Transfection of cells 
2.5.1. Stable transfection of U373 MG cells for overexpression of 
hepaCAM 
U373 MG cells were stably transfected with pcDNA3.1, WT hepaCAM, 
hepaCAM-R92Q and hepaCAM-R92W by Dr Moh Mei Chung. Stable 
transfection of U373 MG cells was performed using Lipofectamine with 
PLUS reagent (Life Technologies) according to the manufacturer’s 
instructions, and cells were selected in culture medium containing 800 μg/ml 
G418 (Sigma-Aldrich, St. Louis, MO, USA) for two weeks before cloning. 
After selection, stable clones were maintained in medium containing 
100 μg/ml G418. 
2.5.2. Stable transfection of MCF7 and HepG2 cells for overexpression 
of hepaCAM 
MCF7 and HepG2 cells were stably transfected with pcDNA6B/V5-His and 
hepaCAM previously by Dr Moh Mei Chung (Moh et al., 2005a; Moh et al., 
2005b). Stable transfection of MCF7 and HepG2 cells was performed using 
Lipofectamine with PLUS reagent according to the manufacturer’s 
instructions, and stable clones were selected and maintained in medium 
containing 10 μg/ml blasticidin (Life Technologies). 
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2.5.3. Transient transfection of HEK293T cells for overexpression of 
hepaCAM  
HEK293T cells were seeded one day before transfection such that they would 
be 70% confluent on the day of transfection. Cells were transfected with 
pcDNA3.1 and GlialCAM-WT-3.1 using Turbofect Transfection Reagent 
(Thermo Scientific), according to the manufacturer’s instructions. For a 24-
well plate, transfection complexes were prepared by mixing 1 μg of plasmid 
DNA with 2 μl transfection reagent in 100 μl Opti-MEM (Life Technologies) 
and added drop-wise to each well. Cells were incubated at 37°C in a CO2 
incubator and harvested 48 h post-transfection for western blot analysis. 
2.5.4. Transient transfection of U373 MG cells for siRNA-mediated 
knockdown of connexin 43 
U373 MG cells were seeded one day before transfection such that they would 
be 50% confluent on the day of transfection. Silencing of connexin 43 
expression was performed using the GJA1 Trilencer-27 Human siRNA kit 
(OriGene, Rockville, MD, USA). Cells were transfected with 5 nM 
connexin 43 siRNA duplex (SR301801C) or universal scrambled siRNA 
duplex (SR30004) using Lipofectamine 2000 (Life Technologies), according 
to the manufacturer’s instructions. For a 6-well plate, 4 μl Lipofectamine 2000 
was diluted in 200 μl serum-free medium and incubated for 5 min. 
Appropriate amounts of the siRNA duplexes were diluted separately in 200 μl 
serum-free medium and mixed with the diluted Lipofectamine 2000. The 
mixture was then incubated for another 20 min to allow complex formation to 
occur. Thereafter, the transfection complexes were added drop-wise to each 
well and cells were incubated at 37°C in a CO2 incubator. The knockdown of 
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connexin 43 was evaluated 48 h post-transfection by western blot analysis and 
immunofluorescent staining. 
2.6. Preparation of whole cell extracts for western blot analysis 
Cells grown as a monolayer were rinsed in PBS and scraped in 
radioimmunoprecipitation assay (RIPA) buffer supplemented with a protease 
inhibitor cocktail (1:100 dilution, Sigma-Aldrich). The cell lysate was further 
incubated on ice for 10 min with vortexing and centrifuged at 13,000 rpm for 
10 min at 4°C to pellet the debris. The supernatant was retained and stored 
at -20°C or -80°C until use. 
2.7. Determination of protein concentration by the Bradford assay 
The concentration of protein in the cell lysates was quantified by the Bradford 
assay, a colorimetric protein assay based on the shift in absorbance of the 
Coomassie Brilliant Blue G-250 dye to 595 nm upon binding to protein. The 
working dye solution was prepared by diluting 1 part of the Dye Reagent 
Concentrate (Bio-Rad, Hercules, CA, USA) in 4 parts of deionised water. 
10 μl of the protein sample diluted in PBS was mixed with 200 μl working dye 
solution, and the absorbance at 595 nm (A595) was measured with the 
Bio-Rad Model 680 microplate reader. A standard curve was also computed 
by measuring the A595 of bovine serum albumin (BSA; Biowest) at 
concentrations of 0-1 mg/ml. The concentration of protein in the samples was 
determined based on this standard curve. 
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2.8. Western blot analysis 
2.8.1. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples were resolved by SDS-PAGE using the Bio-Rad Mini-
PROTEAN electrophoresis system. Equal protein amounts were mixed with 
an appropriate amount of 2× or 5× Laemmli sample buffer, and denatured by 
heating at 95°C for 5 min. The samples and a molecular weight reference, 
Precision Plus Protein Prestained Standards (Bio-Rad), were then loaded onto 
a 10% or 12% polyacrylamide gel and resolved at 150 V for 70 min in 1× 
SDS-PAGE running buffer (Life Technologies).  
2.8.2. Protein transfer 
Proteins were transferred from the polyacrylamide gel onto a PVDF 
membrane (Bio-Rad) using the Bio-Rad Mini Trans-Blot system. The PVDF 
membrane was first pre-wet with absolute ethanol until translucent. The 
membrane, gel, filter paper and fibre pads were then equilibrated in Towbin 
buffer for 15 min. The gel sandwich was assembled and proteins were 
transferred from the gel to the membrane at 100 V for 60 min in Towbin 
buffer containing 0.1% SDS. To maintain uniform conductivity and 
temperature during transfer, an ice pack was placed in the tank and the buffer 
was continuously stirred on a stir plate.  
2.8.3. Antibody probing and detection 
After protein transfer, the membrane was rinsed with Tris-buffered saline 
containing 0.1% Tween-20 (TBST), blocked with blocking buffer (5% skim 
milk in TBST) for 1 h at room temperature and probed with primary antibody 
overnight at 4°C. Table 1 lists the primary antibodies used for western blot 
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analysis and their dilutions in blocking buffer. Full-length hepaCAM was 
detected with a commercial antibody (clone 419305) raised against an 
immunogen derived from residues 34-242 of hepaCAM, which approximates 
the hepaCAM extracellular domain. Alternatively, full-length hepaCAM as 
well as the cleaved hepaCAM fragment containing the cytoplasmic domain 
could be detected with a custom-made antibody (clone 5A1F1) raised against 
an epitope comprising residues 357-389 in the hepaCAM cytoplasmic domain, 
or with HRP-conjugated antibodies against the C-terminal FLAG-tag or V5-
tag on the hepaCAM cytoplasmic domain. 
After incubation with primary antibody and washing three times in TBST, 
5 min each, the blot was incubated with horseradish peroxidase (HRP)-
conjugated secondary antibody (1:5,000 dilution in blocking buffer): goat anti-
mouse IgG-HRP (Thermo Scientific, Rockford, IL, USA) or goat anti-rabbit 
IgG-HRP (Santa Cruz Biotechnology, Dallas, TX, USA) for 1-2 h at room 
temperature. The blot was then washed three times with TBST and protein 
bands were detected with SuperSignal West Pico or Femto Chemiluminescent 
Substrate (Thermo Scientific), and exposed to X-ray films (Thermo 
Scientific). 
To re-probe with another antibody, the blot was stripped in a 15-min wash of 
stripping buffer and rinsed in TBST before blocking. 
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Table 1. List of primary antibodies used for western blot analysis. 
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2.9. Immunofluorescence staining and confocal microscopy 
Cells were grown on round glass coverslips in 6-well plates to 70-90% 
confluence and fixed in 4% paraformaldehyde for 10 min at 37°C. They were 
then washed twice with PBS and permeabilised with 0.2% Triton X-100 in 
PBS for 5 min. After another wash with PBS twice, cells were blocked with 
1% BSA in PBS for 1 h at room temperature and incubated with primary 
antibody overnight at 4°C. Table 2 lists the primary antibodies used for 
immunofluorescence staining and their dilutions in 1% BSA. Detection of full-
length hepaCAM was performed with either an antibody against the 
hepaCAM extracellular domain (clone 419305) or with an antibody against 
the hepaCAM cytoplasmic domain (clone 5A1F1). 
Excess primary antibody was removed the next day by washing cells twice 
with PBS. Thereafter, cells were incubated with the secondary antibodies 
Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 594 goat anti-rabbit 
IgG (Life Technologies; both 1:100 dilution in 1% BSA) for 1-2 h at room 
temperature. Cells were subsequently washed twice with PBS and 
counterstained with DAPI for 30 min at 37°C. The coverslips were mounted 
onto glass slides with FluorSave Reagent (Merck Millipore, Billerica, MA, 
USA). Images were captured with an Olympus FluoView FV1000 confocal 
laser scanning microscope (Olympus, Tokyo, Japan) and analysed with 
FV1000 Viewer version 4.1. For confocal z-stack scans, three-dimensional 




Table 2. List of primary antibodies used for immunofluorescence. 
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2.10. Treatment of cells with hepaCAM antibody 
Cells expressing hepaCAM were treated overnight with a monoclonal 
antibody against the hepaCAM extracellular domain (clone 419305) at a 
concentration of 10 μg/ml. Mouse IgG1 (clone MOPC-21; Sigma-Aldrich) 
was included as an isotype control. 
2.11. Co-immunoprecipitation assay 
Co-immunoprecipitation (co-IP) assays were performed to determine whether 
connexin 43 could be co-immunoprecipitated together with WT hepaCAM, 
hepaCAM-R92Q or hepaCAM-R92W. The assays were carried out with or 
without in vivo cross-linking of proteins with dithiobis[succinimidyl 
propionate] (DSP; Thermo Scientific), which stabilises weak or transient 
protein interactions prior to cell lysis. Where cross-linking was performed, 
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cells grown as a monolayer were rinsed twice with PBS and incubated with 
2 mM DSP for 30 min at room temperature. As DSP is water-insoluble, 4 mg 
of DSP was first dissolved in 0.4 ml DMSO and topped up with 4.6 ml PBS, 
and 5 ml of 2 mM DSP was used for a cell culture flask of area 75 cm2. The 
cross-linking reaction was quenched by the addition of 20 mM Tris, pH 7.4 for 
15 min. Thereafter, cells were washed twice with PBS and lysed in a non-
denaturing lysis buffer (1% NP-40 in PBS) supplemented with a protease 
inhibitor cocktail. The protein concentration of the lysates were quantified by 
the Bradford assay as described in section 2.7. Equal protein amounts were 
pre-cleared with Protein G agarose beads (Thermo Scientific) for 1 h at 4°C to 
remove proteins that bind non-specifically to the beads. The pre-cleared 
lysates were then incubated with fresh Protein G agarose beads and 2 μg of 
hepaCAM antibody (clone 419305) or the isotype control (clone MOPC-21) 
overnight at 4°C with agitation. The beads were spun down the next day and 
washed four times with non-denaturing lysis buffer. Subsequently, the beads 
were boiled in 2× Laemmli sample buffer for 10 min to elute bound proteins 
and cleave DSP cross-links. The samples were then analysed by western blot 
to detect co-IP of connexin 43 with hepaCAM. 
2.12. Subcellular fractionation 
Subcellular fractionation of cell lines was performed with the Subcellular 
Protein Fractionation Kit for Cultured Cells (Thermo Scientific), according to 
the manufacturer’s instructions.  The kit enables the sequential separation of 
cytoplasmic, membrane, soluble nuclear, chromatin-bound and cytoskeletal 
fractions from cell cultures. 
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Cells were harvested with 1× trypsin-EDTA and washed with ice-cold PBS. 
All subsequent incubations and centrifugations were performed at 4°C, and 
the samples and extraction buffers were kept on ice at all times, unless 
otherwise stated. For a cell pellet with a packed volume of approximately 
20 μl, 200 μl Cytoplasmic Extraction Buffer containing protease inhibitors 
was added and mixed gently for 10 min on a rotary shaker to selectively 
permeabilise the plasma membrane and release soluble cytoplasmic contents. 
After centrifugation at 500 × g for 5 min, the supernatant was retained as the 
cytoplasmic extract. The pellet was then lysed with 200 μl Membrane 
Extraction Buffer containing protease inhibitors by vortexing for 5 s at the 
maximum speed, and further incubation for 10 min with gentle mixing. The 
Membrane Extraction Buffer solubilises the contents of the plasma, 
mitochondria, ER and Golgi membranes, but not the nuclear membranes. The 
sample was then centrifuged at 3,000 × g for 5 min and the supernatant was 
retained as the membrane extract. Next, the pellet containing intact nuclei was 
lysed with 100 μl Nuclear Extraction Buffer (NEB) supplemented with 
protease inhibitors. The sample was vortexed for 15 s at the maximum speed, 
and further incubated for 30 min with gentle mixing. The lysate was then 
centrifuged at 5,000 × g for 5 min and the supernatant was retained as the 
soluble nuclear extract. To release chromatin-bound nuclear proteins, 100 μl 
room temperature NEB containing protease inhibitors, CaCl2 and micrococcal 
nuclease was added to the recovered pellet and vortexed for 15 s at the 
maximum speed. After further incubation at 37°C for 5 min and vortexing for 
another 15 s, the lysate was centrifuged at 16,000 × g for 5 min and the 
supernatant was retained as the chromatin-bound nuclear extract. 100 μl room 
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temperature Pellet Extraction Buffer containing protease inhibitors was then 
added to the remaining insoluble pellet, vortexed for 15 s at the maximum 
speed and incubated at room temperature for 10 min. Finally, the lysate was 
centrifuged at 16,000 × g for 5 min, and the supernatant retained as the 
cytoskeletal extract. The fractions were stored at -80°C until use. 20 μg of 
each fraction was loaded onto a gel for western blot analysis. 
For experiments involving only cytoplasmic and membrane protein extraction, 
the cytoplasmic and membrane extracts were prepared as described above and 
analysed by western blot, together with the remaining pellet containing the un-
separated nuclear and cytoskeletal contents. 
2.13. Isolation of total RNA from cells 
Total RNA was extracted from cell cultures with the RNeasy Mini Kit 
(Qiagen, Hilden, Germany) as per the manufacturer’s instructions. Cells were 
lysed in 350 μl Buffer RLT with β-mercaptoethanol and homogenised by 
vigorous pipetting. An equal volume of 70% ethanol was added to the cell 
lysate and mixed. The cell lysate was transferred to an RNeasy spin column 
and centrifuged. The immobilised RNA was then washed with 350 μl Buffer 
RW1 and subjected to on-column DNase digestion with the RNase-Free 
DNase Set (Qiagen) to remove trace genomic DNA contamination. DNase I 
mix containing 10 μl DNase I stock solution and 70 μl Buffer RDD was added 
directly to the column and incubated for 15 min at room temperature. 
Thereafter, the column was washed once with 350 μl Buffer RW1 and twice 
with 500 μl Buffer RPE. The RNA was eluted with RNase-free water and the 
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concentration was quantified using the NanoDrop spectrophotometer (Thermo 
Scientific). The RNA was stored at -80°C until use.  
2.14. Semi-quantitative reverse-transcription-PCR (RT-PCR) 
Connexin 43 expression at the mRNA level was determined 
semi-quantitatively with the OneStep RT-PCR Kit (Qiagen). The enzyme mix 
in the kit contains reverse transcriptases and a hot-start Taq DNA polymerase, 
thus enabling both reverse transcription and PCR to be performed sequentially 
in a single reaction setup. 0.5 μg of total RNA and gene-specific primers were 
used for first-strand cDNA synthesis and subsequent PCR amplification. 
Table 3 shows the sequences of the primers used for amplifying connexin 43 
and the internal control gene GAPDH. The primers for amplifying 
connexin 43 had been described in a previous study by Eugenin et al. (2003). 
Each reaction was set up on ice as described in Table 4 and the RT-PCR was 
performed under the conditions described in Table 5.  
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Table 3. Sequences of primers used in this study. 
Primer Sequence 
Connexin 43  
Cx43-F 5’-GGG TTA AGG GAA AGA GCG ACC-3’ 
Cx43-R 5’-CCC CAT TCG ATT TTG TTC TGC-3’ 
GAPDH  
GAPDH-F 5’-CGG ATT TGG TCG TAT TGG GC-3’ 
GAPDH-R 5’-GGC AGA GAT GAT GAC CCT TTT G-3’ 
 
Table 4. Semi-quantitative RT-PCR reaction components. 
Component Volume (μl) 
Master mix  
RNase-free water 15 − x 
5× RT-PCR buffer 5 
dNTP mix (10 mM) 1 
Forward primer (10 μM) 1.5 
Reverse primer (10 μM) 1.5 
RT-PCR enzyme mix 1 
Template RNA x 
Total volume 25  
 
Table 5. Semi-quantitative RT-PCR conditions. 
 Temperature Time Cycles 
Reverse transcription 50°C 30 min 1 
Initial PCR activation 95°C 15 min 1 
    
Denaturation 94°C 30 s  
Annealing 50°C 30 s 34 
Extension 72°C 1 min  
    




2.15. Agarose gel electrophoresis 
The products of RT-PCR were resolved in a 1.5% agarose gel. To prepare the 
gel, 0.6 g of agarose was dissolved completely in 40 ml of 1× Tris-acetate-
EDTA (TAE) buffer (Vivantis, Malaysia) by microwaving. A 1:10,000 
dilution of GelGreen (Biotium, Hayward, CA, USA) was added to the cooled 
agarose mixture before casting the gel. Once set, the gel was submerged in an 
electrophoresis tank filled with 1× TAE buffer. Samples and 1 kb DNA 
Ladder (Promega) were mixed with an appropriate amount of 6× Blue/Orange 
Loading Dye (Promega) and loaded onto the gel. The gel was electrophoresed 
at 100 V for 40 min and viewed with a UV transilluminator. 
2.16. Cycloheximide chase assay 
To determine the stability of connexin 43 protein, cells were treated with 
50 μg/ml cycloheximide (CHX; Sigma-Aldrich), a potent inhibitor of protein 
synthesis. At each time-point (0, 30, 60 and 90 min), cells were lysed in RIPA 
buffer supplemented with a protease inhibitor cocktail. Equal protein amounts 
were analysed by western blot and GAPDH was used as a loading control. 
2.17. Quantification of western blot using ImageJ 
The densities of western blot bands were quantified using the gel analysis 
method in ImageJ (National Institutes of Health, Bethesda, MD, USA). For the 
CHX chase assay, the densities of the connexin 43 bands were normalised to 
the densities of the respective GAPDH bands at each time-point. 
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2.18. Cell adhesion assay 
The attachment of hepaCAM-expressing cells to fibronectin was quantitated 
as detailed below, with reference to the methods described by Humphries 
(2001) and Akiyama (2002). 
2.18.1. Preparation of fibronectin-coated plates 
Glass coverslips or cell culture plates were coated with 10 μg/ml fibronectin 
from bovine plasma (Sigma-Aldrich) overnight at 4°C. Any remaining 
uncoated sites in the fibronectin-coated wells were blocked with 1% BSA for 
30-60 min prior to the assay.  
Separate coverslips or wells were coated with 0.1% poly-L-lysine (Sigma-
Aldrich) as a non-integrin ligand control. 
2.18.2. Adhesion of cells to fibronectin 
Prior to performing the adhesion assay, cells were starved in serum-free 
medium overnight to remove extracellular and exogenous stimulatory factors 
present in FBS, thus ensuring that their adhesion to fibronectin is solely due to 
integrin-mediated signalling. The next day, serum starved cells were gently 
detached with StemPro Accutase cell dissociation reagent (Life Technologies) 
and resuspended in serum-free medium to a density of 2 × 105 cells/ml. Cells 
were then allowed to adhere to fibronectin-coated wells at 37°C for 5 min, or 
longer where indicated. Unattached or loosely adherent cells were removed by 
gently washing wells three times with PBS. Attached cells were subsequently 
fixed in 4% paraformaldehyde and analysed by immunofluorescence staining 
or quantitated by crystal violet staining. 
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2.18.3. Crystal violet staining 
To quantitate the attachment to fibronectin, cells were stained with 0.1% 
crystal violet for 60 min. Excess dye was removed by washing the wells three 
times with water. The bound dye was subsequently solubilised with 10% 
acetic acid and the A595 was measured with the Bio-Rad Model 680 
microplate reader. Background crystal violet staining was determined from 
blank wells that had been coated with 1% BSA, and was subtracted from all 
experimental results. A standard curve correlating A595 values and cell 
numbers was computed by allowing known numbers of cells to fully adhere to 
poly-L-lysine-coated wells. The percentage of cells adhering to fibronectin 
was subsequently calculated from the A595 measurements with reference to 
the standard curve. 
2.19. Wound healing assay 
Cell migration was assessed by wound healing assays. Cells were grown to 
confluence in 6-well plates and transfected with connexin 43 siRNA or 
scrambled siRNA. At 24 h post-transfection, confluent monolayers were 
scratched with a sterile plastic 200 μl micropipette tip to generate wounds. The 
scratch wounds were viewed using the Axiovert 40 inverted microscope (Carl 
Zeiss, Jena, Germany) and three representative wound sites were marked out 
on the plate. Microscopic images of these wound sites were taken at 0, 24 and 
48 h. The percentage wound closure was determined by measuring the width 
of the remaining unfilled spaces of the wounds. 
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2.20. 3H-thymidine incorporation assay 
Cell proliferation was quantified by the incorporation of 3H-thymidine. Cells 
were transfected with connexin 43 siRNA or scrambled siRNA. At 24 h post-
transfection, cells were detached and seeded in replicate wells of a 96-well 
plate at 10% confluence. After culturing for another 24 h, cells were pulsed 
with 0.5 µCi 3H-thymidine (Perkin Elmer, Waltham, MA, USA) and incubated 
at 37°C in a CO2 incubator overnight. The next days, cells were lysed by 
freezing and harvested onto a Packard Unifilter Plate using the MicroMate 196 
Cell Harvester (Packard Instruments, Meridien, CT, USA). The plate was 
dried at 56°C for 1-2 h, after which 20 µl MicroScint solution (Perkin Elmer) 
was added to each well. Radioactivity was measured using the TopCount 
liquid scintillation analyser (Packard Instruments). 
2.21. Cell aggregation and anoikis assay 
Cells were grown as aggregates under anchorage-independent conditions and 
assayed for anoikis, with reference to the methods described by Weng et al. 
(2002) and Zhang et al. (2010b). 
2.21.1. Culture of cells under anchorage-independent conditions 
Anchorage-independent culture conditions were created by coating 60 mm 
culture dishes twice with 2.5 ml polyhydroxyethylmethacrylate (poly-HEMA; 
Sigma-Aldrich) solution (12 mg/ml in 95% ethanol) and drying overnight at 
50-60°C. Prior to use, the dishes were rinsed twice with PBS to remove 
residual ethanol. Cells grown as a monolayer were subsequently detached with 
StemPro Accutase and resuspended in culture medium as a single-cell 
suspension. They were then seeded onto the poly-HEMA-coated culture 
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dishes at a density of 1 × 105 cells/ml and incubated at 37°C in a CO2 
incubator overnight. Under these anchorage-independent conditions, cells will 
tend to cluster together and grow as aggregates. 
2.21.2. Determination of cell aggregate volume 
Cells were stained with 1.5 μM calcein-AM (Life Technologies) for 20 min at 
37°C, detached and seeded onto poly-HEMA-coated culture dishes as 
described above. After incubation at 37°C overnight, the aggregates were 
visualised by confocal microscopy and confocal z-stacks were analysed as 
described in section 2.9. Three-dimensional rendering of the aggregates was 
performed and the volume of each individual aggregate was determined. The 
spheroid volume threshold was set at 100,000 μm3 and values below this 
threshold were excluded from statistical analysis as they tended to be single 
cells or loose clumps of cells. 
2.21.3. Determination of anoikis by flow cytometry 
Anoikis is a form of apoptosis induced in anchorage-dependent cells when 
there is a loss of attachment to the ECM. To determine anoikis, cells were 
grown under anchorage-independent conditions as described above. After 
incubation at 37°C overnight, the aggregates were harvested and dissociated 
with StemPro Accutase into a single-cell suspension. Anoikis was determined 
by the annexin V/7-AAD apoptosis assay described in section 2.22.2. Cells 
grown as monolayer cultures were included as controls to determine the 
baseline apoptosis rates. 
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2.22. Flow cytometry 
2.22.1. Detection of binding to fibronectin 
To detect binding of hepaCAM to fibronectin by fluorescence activated cell 
sorting (FACS), serum starved cells were gently detached with StemPro 
Accutase cell dissociation reagent, washed and blocked in 1% BSA for 
10 min.  Cells were subsequently incubated with 50 μg/ml HiLyte Fluor 488-
labeled fibronectin from bovine plasma (Cytoskeleton Inc., Denver, CO, USA) 
diluted in 1% BSA for 15 min at room temperature. No fibronectin was added 
for the negative control. Flow cytometry was performed on a CyAn ADP 
Analyser (Beckman Coulter, Brea, CA, USA). Data were analysed using 
Summit version 4.3.1 (Beckman Coulter). 
2.22.2. Annexin V/7-AAD apoptosis assay 
Apoptosis was determined by annexin V/7-AAD staining. Briefly, cells were 
washed twice with cold PBS and resuspended in 1× Binding Buffer 
(eBioscience, San Diego, CA, USA). For a 100 μl cell suspension, 2.5 μl 
Annexin V-Alexa Fluor 647 (BioLegend, San Diego, CA, USA) and 5 μl 
7-AAD (eBioscience) were added and incubated in the dark for 15 min at 
room temperature. Thereafter, 400 μl 1× Binding Buffer was added to each 
sample and flow cytometry was performed as described above. 
2.23. Calcein-AM transfer assay 
Gap junction activity or intercellular communication was quantified using a 
well-established method described by Kiang et al. (1994) and Czyz et al. 
(2000). In this method, cells are labelled with two dyes: DiI (red), a 
fluorescent lipophilic dye that binds to cell membranes, and calcein-AM, the 
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acetoxymethyl ester derivative of calcein (green). Calcein-AM is non-
fluorescent until hydrolysed in the cytoplasm by esterases to calcein, which is 
small enough to be transferred between cells via gap junctions. Cells labelled 
with DiI and calcein-AM (“donor cells”) are co-cultured with unstained cells 
(“recipient cells”) from the same cell line. Recipient cells that have taken up 
calcein via GJIC will be stained green only, and can be distinguished from 
donor cells which will be stained both red and green. The amount of gap 
junction activity can be correlated to the percentage of cells in which 
calcein-AM transfer has occurred, as measured by flow cytometry. 
In this study, donor cells and recipient cells were seeded separately into a 12-
well plate and 100 mm culture dish respectively, and cultured overnight. 
Donor cells were labelled with 1 μM Vybrant DiI (Life Technologies) and 
5 μM calcein-AM (Life Technologies) for 20 min at 37°C, and washed twice 
with PBS to remove excess dye. Both donor and recipient cells were 
dissociated with 0.2× trypsin-EDTA, mixed at a ratio of 1:40 (donor:recipient) 
and co-cultured overnight (15 h) at 37°C in a 100 mm dish. The next day, cells 
were harvested with 0.2× trypsin-EDTA and fixed in 1% paraformaldehyde. 
Flow cytometry was performed on a Fortessa Cell Analyser (BD Biosciences, 
San Jose, CA, USA). Data were analysed using FlowJo version 7.6.1 (FlowJo 
LLC, Ashland, OR, USA). 
2.24. Statistical analysis 
Statistical analyses for all experimental data were performed using GraphPad 
Prism version 5.01 (La Jolla, CA, USA). Statistical significance was 
determined by a two-tailed unpaired Student’s t-test, or one-way analysis of 
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variance (ANOVA) with Tukey’s multiple comparisons test. Values of 
p < 0.05 were considered significant. 
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CHAPTER 3 RESULTS 
3.1 Interaction of hepaCAM with connexin 43 
This section discusses the experiments to study the functions of hepaCAM in 
relation to the gap junction protein connexin 43 in U373 MG glioblastoma 
cells. 
3.1.1. hepaCAM co-localises with connexin 43 at the cell-cell contacts of 
U373 MG cells 
Several studies have shown an abnormal localisation of connexin 43 in the 
cytoplasm of tumour cells, instead of the cell membrane (reviewed in Mesnil 
et al., 2005). In glioblastoma, previous studies had found a predominant 
localisation of connexin 43 in the cytoplasmic perinuclear region in three 
different glioblastoma cell lines (Cottin et al., 2008), as well as in four out of 
eight primary glioblastoma cultures established from clinical cases (Cottin et 
al., 2011). Conversely in non-neoplastic brain tissues, connexin 43 was 
localised to regions of cell-cell contact, characteristic of gap junctions between 
astrocytes (Cottin et al., 2011).  
To investigate whether the expression of hepaCAM influences connexin 43 
localisation in glioblastoma cells, the U373 MG cell line, which does not 
endogenously express hepaCAM, was stably transfected with WT hepaCAM 
and the corresponding empty vector and stained for connexin 43. Similar to 
previous findings in glioblastoma cells (Cottin et al., 2008), connexin 43 in 
vector-transfected U373 MG cells had a diffused staining in the cytoplasm and 
perinuclear region, and there was little staining for connexin 43 at the cell 
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membrane and at cell-cell contacts (Figure 6). On the other hand, in U373 MG 
cells expressing WT hepaCAM, connexin 43 was redistributed to the cell 
membrane, particularly at sites of cell-cell contacts, where strong co-
localisation of connexin 43 with hepaCAM could be observed. Connexin 43 
also co-localised with hepaCAM in distinct punctuate structures scattered 
throughout the cytoplasm, and there was comparatively less staining for 
connexin 43 in the perinuclear region compared to control cells. These 
punctuate structures are reminiscent of vesicles of the endomembrane system, 
and thus suggested that hepaCAM may play a role in the vesicular transport of 
connexin 43 to cellular junctions.  
As mentioned previously, mutations in hepaCAM can cause the disease MLC. 
We next examined the effects of these mutations on connexin 43 localisation 
in U373 MG cells. We selected two naturally occurring mutations in which the 
arginine residue in the 92nd amino acid position had been replaced with 
glutamine (R92Q) or with tryptophan (R92W) (Lopez-Hernandez et al., 
2011a). These single amino acid substitutions occur in the hepaCAM 
extracellular domain, specifically the first Ig-like domain. 
As shown in Figure 6, the subcellular distribution of connexin 43 in U373 MG 
cells expressing hepaCAM-R92Q or hepaCAM-R92W was similar to the 
vector-transfected cells as connexin 43 was localised mainly in the cytoplasm 
and perinuclear region. Compared to cells expressing WT hepaCAM, there 
was reduced localisation of both connexin 43 and mutant hepaCAM at cell-
cell contacts. Although co-localisation of connexin 43 with mutant hepaCAM 
could still be observed, it occurred mainly in intracellular compartments and 
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not at cell-cell contacts, which suggested that the R92Q and R92W mutations 
may inhibit the ability of hepaCAM to target connexin 43 to cellular junctions, 




Figure 6. hepaCAM co-localises with connexin 43 at the cell-cell contacts of U373 MG cells, and mutations in the hepaCAM 
extracellular domain prevent its association with connexin 43 at the cell-cell contacts. Cells were stably transfected with pcDNA3.1 vector, 
wild-type hepaCAM, hepaCAM-R92Q (next page) and hepaCAM-R92W (next page). Immunofluorescent staining was performed with 
antibodies against the hepaCAM cytoplasmic domain (green) and connexin 43 (red). Co-localisation of hepaCAM and connexin 43 is indicated 
by yellow fluorescence. Nuclei were stained with DAPI (blue). Insets show a higher magnification of sites of cell-cell contacts. Cells were 
visualised by confocal microscopy under a 60× objective. The images presented are representative of images taken from at least six different 
fields. Scale bar: 10 µm. 
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Figure 6 (continued). hepaCAM co-localises with connexin 43 at the cell-cell contacts of U373 MG cells, and mutations in the hepaCAM 
extracellular domain prevent its association with connexin 43 at the cell-cell contacts. Cells were stably transfected with pcDNA3.1 vector 
(previous page), wild-type hepaCAM (previous page), hepaCAM-R92Q and hepaCAM-R92W. Immunofluorescent staining was performed with 
antibodies against the hepaCAM cytoplasmic domain (green) and connexin 43 (red). Co-localisation of hepaCAM and connexin 43 is indicated 
by yellow fluorescence. Nuclei were stained with DAPI (blue). Insets show a higher magnification of sites of cell-cell contacts. Cells were 
visualised by confocal microscopy under a 60× objective. The images presented are representative of images taken from at least six different 
fields. Scale bar: 10 µm. 
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3.1.2. hepaCAM can be co-immunoprecipitated with connexin 43 
As immunofluorescent studies showed an association of WT hepaCAM with 
connexin 43 at the cell-cell contacts of U373 MG cells, we next verified the 
physical interaction of these two proteins by a co-IP assay. Protein lysates 
were prepared from U373 MG cells stably transfected with WT hepaCAM, 
and WT hepaCAM was precipitated using an antibody against the hepaCAM 
extracellular domain. As shown in Figure 7, connexin 43 could be co-
precipitated together with WT hepaCAM, indicating that hepaCAM co-
localises and interacts with connexin 43. 
 
 
Figure 7. Co-immunoprecipitatation of connexin 43 and hepaCAM. Cell 
lysates were prepared from U373 MG cells stably transfected with pcDNA3.1 
vector and wild-type hepaCAM (fused to a C-terminal 3×FLAG epitope), and 
immunoprecipitated with antibody against the hepaCAM extracellular domain 
(IP hepaCAM). Immunoprecipitation with mouse IgG1 (IP IgG) was included 
as a negative control. Western blot analysis was performed on the 
immunoprecipitates and input (3%) using connexin 43 antibody. The 
efficiency of hepaCAM immunoprecipitation was evaluated with an HRP-
conjugated FLAG antibody. The IgG heavy chain detected with an HRP-
conjugated anti-mouse antibody is shown as a loading control for the IP 
antibodies. The result presented is a representative experiment of two 
independent experiments with similar results. 
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3.1.3. Mutations in hepaCAM weaken the interaction of hepaCAM with 
connexin 43 
We next examined whether the R92Q and R92W mutations in the hepaCAM 
extracellular domain affect the physical interaction of hepaCAM with 
connexin 43 in U373 MG cells. WT hepaCAM and hepaCAM containing the 
R92Q and R92W mutations were precipitated from the protein lysates using 
an antibody against the hepaCAM extracellular domain. Interestingly, 
connexin 43 could be co-precipitated to a higher extent with WT hepaCAM 
than with hepaCAM-R92Q or hepaCAM-R92W (Figure 8A). This was not 
due to less precipitation of hepaCAM-R92Q and hepaCAM-R92W, since the 
levels of hepaCAM precipitated were comparable across all three samples 
when the blot was re-probed with an antibody against the FLAG-epitope on 
hepaCAM. Hence, the results suggested that connexin 43 had a lower affinity 
with these mutations of hepaCAM than with WT hepaCAM. 
The co-IP assay was also repeated with in vivo cross-linking of proteins with 
DSP prior to cell lysis to stabilise low-affinity or transient protein interactions. 
As DSP is lipophilic and membrane-permeable, it is able to cross-link protein 
molecules within the cell, as well as on the cell surface. It was observed that 
connexin 43 could be co-precipitated effectively with WT hepaCAM or with 
hepaCAM containing the R92Q or R92W mutations (Figure 8B). The results 
thus indicated that the binding affinity of hepaCAM for connexin 43 is 
weakened by the R92Q and R92W mutations in the hepaCAM extracellular 
domain, and that connexin 43 could not be co-precipitated effectively with 
mutant hepaCAM unless the physical interaction of the two proteins had been 





Figure 8. Co-immunoprecipitation of wild-type and mutant hepaCAM 
with connexin 43. Mutations in the hepaCAM extracellular domain weaken 
the interaction of hepaCAM with connexin 43. (A) Cell lysates were prepared 
from U373 MG cells stably transfected with wild-type hepaCAM, hepaCAM-
R92Q and hepaCAM-R92W (fused to a C-terminal 3×FLAG epitope). (B) 
Cellular proteins were cross-linked with dithiobis[succinimidyl propionate] 
(DSP) prior to cell lysis. hepaCAM was immunoprecipitated using antibody 
against the hepaCAM extracellular domain (IP hepaCAM). 
Immunoprecipitation with mouse IgG1 (IP IgG) was included as a negative 
control. Western blot analysis was performed on the immunoprecipitates and 
input (2%) using connexin 43 antibody. Efficiency of hepaCAM 
immunoprecipitation was evaluated with an HRP-conjugated FLAG antibody. 
The IgG heavy chain detected with an HRP-conjugated anti-mouse antibody is 
shown as a loading control for the IP antibodies. The result presented is a 




3.1.4. Connexin 43 protein expression is increased in hepaCAM-
expressing U373 MG cells 
Immunofluorescent staining of connexin 43 in WT hepaCAM-expressing 
U373 MG cells (Figure 6) indicated not only a cellular redistribution of 
connexin 43 by hepaCAM but also an increase in connexin 43 expression 
levels. This was confirmed by western blot analysis, which showed a 
significant two-fold increase in connexin 43 protein levels by WT hepaCAM 
compared to vector-transfected control cells (Figure 9A, B). On the other 
hand, the two hepaCAM mutations, especially R92Q, were less effective in 
enhancing connexin 43 expression, as no significant difference in connexin 43 
protein levels was observed between control cells and cells expressing 




Figure 9. Expression of wild-type hepaCAM in U373 MG cells increases 
connexin 43 protein levels. (A) Cell lysates were prepared from U373 MG 
cells stably transfected with pcDNA3.1 vector, wild-type hepaCAM, 
hepaCAM-R92Q and hepaCAM-R92W. 20 μg of cell lysates were subjected 
to western blot analysis using antibodies against connexin 43 and the FLAG-
tag on the hepaCAM cytoplasmic domain. GAPDH was used as a loading 
control. The result presented is a representative experiment of four 
independent experiments with similar results. (B) Quantification of connexin 
43 protein levels in all four independent western blot analyses. Using ImageJ, 
the densities of the connexin 43 bands were normalised to the densities of the 
respective GAPDH bands for each sample, and the mean relative density over 
the four experiments was calculated. The data presented are the means ± SE 




3.1.5. Increased connexin 43 protein expression in hepaCAM-expressing 
cells is not due to upregulation at the transcriptional level 
As western blot analysis showed that connexin 43 protein expression is 
upregulated in WT hepaCAM-expressing U373 MG cells compared to control 
cells, we next sought to understand whether this upregulation occurs at the 
transcriptional or post-transcriptional level. Using primers to amplify a 248-bp 
fragment of connexin 43 mRNA as previously described by Eugenin et al. 
(2003), semi-quantitative RT-PCR was performed to determine connexin 43 
mRNA expression in vector-transfected, WT and mutant hepaCAM-
expressing U373 MG cells (Figure 10). 
 
Figure 10. Evaluation of connexin 43 mRNA expression by semi-
quantitative RT-PCR. Total RNA was isolated from U373 MG cells stably 
transfected with pcDNA3.1 vector, wild-type hepaCAM, hepaCAM-R92Q 
and hepaCAM-R92W. GAPDH was included as a housekeeping gene control, 
while RT-PCR reactions without an RNA template were included as no 
template controls (NTC). The result presented is a representative experiment 
of two independent experiments with similar results. 
 
The results showed that connexin 43 mRNA levels were similar across all four 
cell lines. This indicated that the increased connexin 43 protein levels in WT 
hepaCAM-expressing U373 MG cells are due to an upregulation at the post-
transcriptional level, instead of the transcriptional level. 
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3.1.6. hepaCAM enhances connexin 43 protein stability 
Connexin 43 has been reported to undergo rapid turnover with a short half-life 
of 1-5 h (Beardslee et al., 1998; Laird et al., 1991). We thus hypothesised that 
the increased levels of connexin 43 protein in WT hepaCAM-expressing 
U373 MG cells are due to a slower rate of turnover compared to control cells. 
To assess whether hepaCAM influences connexin 43 protein stability in 
U373 MG cells, the kinetics of connexin 43 degradation were determined by a 
cycloheximide chase assay. Cycloheximide is a potent inhibitor of 
translational elongation and is commonly used to investigate the stability of a 
target protein without confounding contributions from newly synthesised 
proteins. Control and WT hepaCAM-expressing U373 MG cells were treated 
with cycloheximide in a time-course experiment of up to 90 min and harvested 
at intervals of 30 min to determine the amounts of connexin 43 protein 
remaining. 
Compared to vector-transfected cells, cells expressing WT hepaCAM had 
increased stability of connexin 43 as shown by its slower rate of degradation. 
Upon 90 min of inhibition with cycloheximide, the percentage of connexin 43 
protein remaining in vector-transfected U373 MG cells was 27% while that 
remaining in WT hepaCAM-expressing U373 MG cells was 81% (Figure 
11A, B). The results suggested that the binding of hepaCAM to connexin 43 
slows down its rate of degradation and increases its half-life. Thus, the 
increased levels of connexin 43 protein observed in WT-hepaCAM-expressing 







Figure 11. Evaluation of connexin 43 protein stability by cycloheximide 
chase assay. (A) U373 MG cells stably transfected with pcDNA3.1 vector or 
wild-type hepaCAM were treated with cycloheximide (CHX) (50 μg/ml) for 
the times indicated. At each time-point, cells were lysed and 30 μg of cell 
lysates were subjected to western blot analysis using connexin 43 antibody. 
GAPDH was used as a loading control. The result presented is a representative 
experiment of three independent experiments with similar results. (B) 
Summary of the quantification of all three independent CHX chase 
experiments using ImageJ. The densities of the connexin 43 bands were 
normalised to the densities of the respective GAPDH bands at each time-point. 
The level of connexin 43 remaining at each time-point was calculated as a 
percentage of the initial connexin 43 level (time 0 of CHX treatment). The 




3.1.7. Expression of hepaCAM in HEK293T cells leads to increased 
connexin 43 protein levels 
To determine whether hepaCAM also regulates connexin 43 protein levels in 
other cell lines, we transiently transfected WT hepaCAM in human embryonic 
kidney HEK293T cells, which have a high transfection efficiency of 85% 
(Supplementary Figure 1) and low levels of endogenous connexin 43 
expression. Exogenous expression of hepaCAM in HEK293T cells led to a 
significant 1.5-fold increase in connexin 43 protein levels (Figure 12A, B), 
further supporting our previous observation that hepaCAM enhances 
connexin 43 protein stability. It should be noted that connexin 43 was detected 
as two bands in the HEK293T cells, as connexin 43 is well-known to undergo 
post-translational modifications such as phosphorylation, giving rise to shifts 
in the electrophoretic mobility. Based on these results, it is observed that 












Figure 12. Expression of hepaCAM in HEK293T cells increases 
connexin 43 protein levels. (A) HEK293T cells were transiently transfected 
with pcDNA3.1 vector or wild-type hepaCAM. Two days after transfection, 
cells were lysed and 60 μg of cell lysates were subjected to Western blot 
analysis using antibodies against connexin 43 and the hepaCAM extracellular 
domain. GAPDH was used as a loading control. The result presented is a 
representative experiment of three independent experiments with similar 
results. (B) Summary of the quantification of all three experiments using 
ImageJ. The densities of the connexin 43 bands were normalised to the 
densities of the respective GAPDH bands for each sample, and the mean 
relative density over the three experiments was calculated. The data presented 
are the means ± SE (n = 3), *** p < 0.0001 as assessed by t-test. 
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3.1.8. Treatment with an antibody against the hepaCAM extracellular 
domain affects connexin 43 localisation at cell-cell contacts 
As observed previously in Figure 6, the R92Q and R92W mutations in the 
hepaCAM extracellular domain appear to impair the targeting of connexin 43 
to the cell-cell contacts of U373 MG cells. We next sought to understand 
whether neutralisation of hepaCAM with an antibody would also have similar 
effects on connexin 43 localisation. 
U373 MG cells expressing WT hepaCAM were treated overnight with an 
antibody against the hepaCAM extracellular domain, and stained for 
connexin 43 (Figure 13). In cells treated with the IgG control, connexin 43 
was localised mainly to cell junctions, where co-localisation with hepaCAM 
was also observed, in accordance with previous findings. On the other hand, 
treatment of cells with the hepaCAM antibody significantly reduced 
connexin 43 localisation at cell-cell contacts. Diffused staining of connexin 43 
in the cytoplasm and perinuclear region of the cells was observed, and the 
overall expression of connexin 43 appeared to be diminished. Treatment of 
cells with the hepaCAM antibody also abrogated connexin 43 co-localisation 
with hepaCAM. 
Hence, similar to the mutations in the hepaCAM extracellular domain, 
neutralisation of hepaCAM with an antibody against its extracellular domain 
disrupts connexin 43 targeting to the junctions of U373 MG cells. Taken 
together, the data suggest that it is the extracellular domain of hepaCAM 
which interacts with connexin 43, and that the physical interaction of 
hepaCAM with connexin 43 aids in targeting connexin 43 to cell-cell contacts. 
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Neutralisation of hepaCAM with the antibody disrupts the interaction with 
connexin 43, resulting in an intracellular accumulation of connexin 43 and 




Figure 13. Treatment of hepaCAM-expressing U373 MG cells with an antibody against the hepaCAM extracellular domain prevents the 
association of hepaCAM with connexin 43 at cell-cell contacts. Wild-type hepaCAM-expressing U373 MG cells were treated overnight with 
antibody against the hepaCAM extracellular domain in soluble form (10 μg/ml). Cells were also treated with the isotype mouse IgG1 as a 
control. The next day, cells were fixed and immunofluorescent staining was performed with antibodies against the hepaCAM extracellular 
domain (green) and connexin 43 (red). Co-localisation of hepaCAM and connexin 43 is indicated by yellow fluorescence. Nuclei were stained 
with DAPI (blue). Cells were visualised by confocal microscopy under a 60× objective. The images presented here are representative of images 
taken from at least six different fields. Scale bar: 10 µm. 
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3.1.9. Treatment with an antibody against the hepaCAM extracellular 
domain downregulates connexin 43 expression 
As immunofluorescent staining of connexin 43 in hepaCAM antibody-treated 
cells also suggested an overall reduction in connexin 43 expression, we next 
determined connexin 43 protein levels in WT hepaCAM-expressing U373 MG 
cells upon overnight treatment with hepaCAM antibody. In cells treated with 
the hepaCAM antibody, connexin 43 expression was downregulated compared 
to cells treated with the IgG control (Figure 14). The results suggested that 
hepaCAM antibody treatment of the cells disrupts the interaction of hepaCAM 
with connexin 43 and destabilises connexin 43. Hence, the results further lend 
support to the conclusion that the hepaCAM-connexin 43 interaction enhances 
the stability of connexin 43 protein. 
 
 
Figure 14. Treatment of hepaCAM-expressing U373 MG cells with an 
antibody against the hepaCAM extracellular domain causes a 
downregulation of connexin 43 expression. Wild-type hepaCAM-expressing 
U373 MG cells were treated overnight with antibody against the hepaCAM 
extracellular domain in soluble form (10 μg/ml). Cells were also treated with 
the isotype mouse IgG1 as a control. The next day, cells were lysed and 20 μg 
of cell lysates were subjected to western blot analysis using connexin 43 
antibody. GAPDH was used as a loading control. The result presented is a 




Since western blot analysis showed an overall decrease in connexin 43 
expression upon treatment with hepaCAM antibody, we next wanted to 
determine whether the downregulation occurred in the cytoplasmic and 
membrane compartments. Subcellular protein fractionation to isolate the 
cytoplasmic and membrane extracts was performed on WT hepaCAM-
expressing U373 MG cells upon overnight treatment with hepaCAM antibody. 
The membrane extract obtained from subcellular fractionation is a mixture of 
the contents of the plasma, mitochondria, ER and Golgi membranes. As 
shown in Figure 15, compared to IgG-treated cells, connexin 43 levels were 
reduced in both the cytoplasmic and membrane fractions from hepaCAM 
antibody-treated cells. This corroborates the results in Figure 14 which 
showed an overall decrease in connexin 43 expression upon hepaCAM 
antibody treatment and confirms that connexin 43 is destabilised when its 
interaction with hepaCAM is disrupted. 
It should also be noted that while immunofluorescent staining showed a 
marked reduction in connexin 43 expression at the plasma membrane upon 
hepaCAM antibody treatment (Figure 13), there was only a moderate decrease 
in connexin 43 protein levels in the membrane fraction, which contains the 
contents of the endomembrane system in addition to the plasma membrane 
(Figure 15). As a diffused intracellular localisation of connexin 43 was also 
observed upon hepaCAM antibody treatment (Figure 13), the results taken 
together suggested that hepaCAM antibody treatment may also cause an 
accumulation of connexin 43 in the compartments of the endomembrane 
system, for example the ER and Golgi membranes due to impaired targeting to 
the plasma membrane. Alternatively, connexin 43 may accumulate in 
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endosomal and lysosomal compartments due to its decreased stability and 
increased rate of turnover upon hepaCAM antibody treatment. 
 
 
Figure 15. Treatment of hepaCAM-expressing U373 MG cells with an 
antibody against the hepaCAM extracellular domain causes a 
downregulation of connexin 43 expression in both cytoplasmic and 
membrane fractions. Wild-type hepaCAM-expressing U373 MG cells were 
treated overnight with antibody against the hepaCAM extracellular domain in 
soluble form (10 μg/ml). Cells were also treated with the isotype mouse IgG1 
as a control. The next day, cells were detached and subjected to subcellular 
fractionation to isolate the cytoplasmic (C) and membrane (M) fractions. The 
membrane fraction contains the contents of the plasma, mitochondria, ER and 
Golgi membranes. The pellet refers to the residue after extraction of the 
cytoplasmic and membrane fractions. 20 μg of each fraction and the pellet 
were subjected to western blot analysis using connexin 43 antibody. EGFR 





3.1.10. Connexin 43 knockdown does not affect hepaCAM localisation 
Since hepaCAM expression in U373 MG cells targets connexin 43 to cellular 
junctions, we wanted to determine whether the converse was true, i.e. whether 
the presence of connexin 43 influences hepaCAM localisation at cell-cell 
contacts. WT hepaCAM-expressing U373 MG cells were subjected to siRNA-
mediated silencing of connexin 43 expression to determine hepaCAM 
localisation in the absence of connexin 43. The siRNA duplex used and its 
concentration were first optimised (Supplementary Figure 2). 
The efficiency of connexin 43 knockdown in WT hepaCAM-expressing U373 
MG cells was verified by western blot analysis (Figure 16) and the subcellular 
localisation of hepaCAM and connexin 43 was analysed by confocal 
microscopy (Figure 17). As shown by western blot analysis, connexin 43 
protein expression could be effectively silenced in WT hepaCAM-expressing 
U373 MG cells 48 h after transfection with connexin 43 siRNA. The 
knockdown of connexin 43 expression did not affect the overexpression of 
WT hepaCAM in U373 MG cells, as their levels were comparable between 
connexin 43 siRNA-transfected cells and scrambled siRNA-transfected cells 
(Figure 16). In addition, immunofluorescent staining showed that silencing of 
connexin 43 in WT hepaCAM-expressing U373 MG cells also did not affect 
the subcellular localisation of hepaCAM, as well as the overall morphology of 
the cells (Figure 17). This indicates that connexin 43 is not necessary for the 
targeting of hepaCAM to cellular junctions and suggests that hepaCAM can 
function independently of connexin 43. These results also parallel the findings 
by previous studies that MLC1 is not necessary for hepaCAM targeting to 
cellular junctions (Lopez-Hernandez et al., 2011b). 
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Figure 16. siRNA-mediated knockdown of connexin 43 in hepaCAM-
expressing U373-MG cells. Wild-type hepaCAM-expressing U373 MG cells 
were transfected with 5 nM connexin 43 siRNA or scrambled siRNA and 
lysed 48 h post-transfection. 20 μg of cell lysates were subjected to western 
blot analysis using connexin 43 antibody. Full-length hepaCAM was detected 
with an antibody against the hepaCAM cytoplasmic domain. GAPDH was 
used as a loading control. The result presented is a representative experiment 




Figure 17. Silencing of connexin 43 does not affect hepaCAM localisation in U373 MG cells. Wild-type hepaCAM-expressing U373 MG 
cells were transfected with 5 nM scrambled siRNA or connexin 43 siRNA. Cells were fixed 48 h post-transfection and immunofluorescent 
staining was performed with antibodies against the hepaCAM extracellular domain (green) and connexin 43 (red). Co-localisation of hepaCAM 
and connexin 43 is indicated by yellow fluorescence. Nuclei were stained with DAPI (blue). Cells were visualised by confocal microscopy under 
a 60× objective. The images presented here are representative of images taken from at least six different fields. Scale bar: 10 µm. 
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3.1.11. Connexin 43 knockdown does not affect the functions of hepaCAM 
in cell adhesion, migration and proliferation 
Since hepaCAM interacts with and stabilises connexin 43, we postulated that 
connexin 43 may be involved in the functions of hepaCAM in U373 MG cells. 
Since hepaCAM expression in U373 MG cells has been shown to increase 
adhesion, reduce migration and inhibit proliferation (Lee et al., 2009), we 
investigated whether the depletion of connexin 43 in WT hepaCAM-
expressing U373 MG cells influenced these functions of hepaCAM. 
Connexin 43 expression in vector-transfected and WT-hepaCAM U373 MG 
cells was silenced by siRNA-mediated knockdown, and their adhesion to 
fibronectin-coated culture plates was quantified by crystal violet staining 
(Figure 18). The expression of WT hepaCAM led to a significant two-fold 
increase in adhesion to fibronectin compared to vector-transfected cells, in 
accordance with previous findings in U373 MG cells. However, no significant 
difference in adhesion was observed upon connexin 43 knockdown in both 






Figure 18. Silencing of connexin 43 does not affect the increased adhesion 
of hepaCAM-expressing U373 MG cells to fibronectin. Vector-transfected 
and wild-type hepaCAM-expressing U373 MG cells were transfected with 
5 nM scrambled siRNA or connexin 43 siRNA and serum-starved 24 h post-
transfection. After an overnight starvation, cells were detached and allowed to 
adhere to fibronectin-coated plates for 5 min. After 5 min, unattached or 
loosely adherent cells were washed away, and attached cells were fixed and 
stained with crystal violet. The crystal violet stain was subsequently 
solubilised and the A595 measured. The number of cells adhering to 
fibronectin was determined from the A595 measurements with reference to a 
standard curve plotted using A595 values from known numbers of cells, and 
calculated as a percentage of the total number of cells seeded. The data 
represent means ± SD (n = 3), *** p < 0.0001 as assessed by one-way 
ANOVA with Tukey’s multiple comparisons test. The results presented are 




The migration of vector-transfected and WT-hepaCAM U373 MG cells upon 
connexin 43 knockdown was assessed by the wound healing assay (Figure 
19). In accordance with previous findings, hepaCAM expression in U373 MG 
cells significantly reduced cell migration at 24 and 48 h, compared to vector-
transfected cells. Silencing of connexin 43 significantly reduced migration of 
vector-transfected U373 MG cells only at 48 h, and had no significant effects 
on the migration of hepaCAM-expressing U373 MG cells. Thus, the inhibitory 
effects of hepaCAM on cell migration were not reversed or further enhanced 
by connexin 43 knockdown. 
 
 
Figure 19. Silencing of connexin 43 does not affect the reduced migration 
of hepaCAM-expressing U373 MG cells. Vector-transfected and wild-type 
hepaCAM-expressing U373 MG cells were transfected with 5 nM scrambled 
siRNA or connexin 43 siRNA (Cx43 KD), and cell migration was assessed by 
the wound healing assay 24h post-transfection. Confluent monolayers were 
scratched with a pipette tip and the wounds were imaged at 0, 24 and 48 h. 
The sizes of the wounds were measured on the microscopic images to 
calculate the percentage wound closure (mean ± SD, n = 3). *** p < 0.0001 as 
assessed by one-way ANOVA with Tukey’s multiple comparisons test. The 
results presented are representative of three independent experiments with 
similar results.   
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We next quantified the proliferation of vector-transfected and WT-hepaCAM 
U373 MG cells upon connexin 43 knockdown by the incorporation of 
radioactive 3H-thymidine into newly synthesised DNA. While the proliferation 
of WT-hepaCAM-expressing U373 MG cells was significantly inhibited 
compared to vector-transfected cells consistent with previous findings, no 
significant difference in proliferation was observed in both cell lines upon 
connexin 43 knockdown (Figure 20). 
  
 
Figure 20. Silencing of connexin 43 does not affect the anti-proliferative 
effects of hepaCAM in U373 MG cells. Vector-transfected and wild-type 
hepaCAM-expressing U373 MG cells were transfected with 5 nM scrambled 
siRNA or connexin 43 siRNA (Cx43 KD). Cell proliferation was quantified 
48 h post-transfection by the incorporation of 3H-thymidine. Proliferation is 
indicated by counts per minute (cpm). The data represent means ± SE, n = 8. 
*** p < 0.0001 as assessed by one-way ANOVA with Tukey’s multiple 
comparisons test. The results presented are representative of two independent 
experiments with similar results.   
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Thus, the results indicated that connexin 43 in U373 MG cells is not directly 
involved in the functions of hepaCAM in increasing cell adhesion, reducing 
migration and inhibiting proliferation. 
3.1.12. hepaCAM increases gap junction activity in U373 MG cells 
Since hepaCAM expression caused a re-distribution of connexin 43 to the cell 
surface at cell-cell contacts and the main function of connexin 43 is in gap 
junctions, we hypothesised that the hepaCAM-connexin 43 interaction may 
promote gap junction activity. Hence, we investigated gap junction activity in 
hepaCAM-expressing U373 MG cells by the calcein-AM transfer assay as 
described in detail in section 2.23. In this assay, donor cells stained with 
calcein-AM were co-cultured with unstained recipient cells of the same cell 
line and the percentage of recipient cells that have taken up calcein by gap 
junction transfer was measured by flow cytometry (Figure 21A). The 
percentage of control U373 MG cells in which calcein transfer occurred was 
11%, and this was increased to about 23% in hepaCAM-expressing U373 MG 
cells (Figure 21B, C). Thus, the results indicated a two-fold increase in gap 
junction activity upon hepaCAM expression in U373 MG cells.  
The calcein-AM transfer assay was also performed on control and hepaCAM-
expressing MCF7 (Figure 21D, E) and HepG2 cells (Figure 21F, G). 
However, compared to U373 MG cells, the percentage of cells in which 
calcein transfer occurred was much lower at 1-2% in control and hepaCAM-
expressing MCF7 and HepG2 cells. There was slight or no increase in the 
percentage calcein transfer upon hepaCAM expression in MCF7 and HepG2 
cells. The minimal gap junction activity observed can be explained by the lack 
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of endogenous connexin 43 expression in control and hepaCAM-expressing 
MCF7 and HepG2 cells, as shown by a prolonged exposure in western blot 
analysis (Figure 21H). The results taken together indicate that hepaCAM 
specifically increases gap junction activity mediated by connexin 43. 
Additionally, from the prolonged western blot exposure, hepaCAM-expressing 
U373 MG cells appear to have higher levels of post-translationally modified 
connexin 43, as observed by the stronger intensity for the slower-migrating 
bands of connexin 43 (Figure 21H). As discussed in section 1.7.2, connexin 43 
is frequently phosphorylated. Thus, it is likely that these bands are for 
phosphorylated forms of connexin 43 which promote gap junction activity, as 
suggested by the higher gap junction activity in hepaCAM-expressing 






Figure 21. Expression of hepaCAM increases gap junction activity in 
U373 MG cells, but not in MCF7 and HepG2 cells. (A) Schematic for the 
quantification of gap junction activity by the calcein-AM transfer assay. Cells 
labelled with calcein-AM and DiI (donor) were co-cultured overnight with 
unlabelled cells (recipient) at a ratio of 1:40 (donor:recipient) and assayed by 
flow cytometry the next day. Gap junction activity is correlated to the 
percentage of calcein-positive recipient cells in (B) U373 MG cells stably 
transfected with the pcDNA6B/V5-His empty vector and (C) U373 MG cells 
stably transfected with hepaCAM. The results presented are representative of 





Figure 21 (continued). Expression of hepaCAM increases gap junction 
activity in U373 MG cells, but not in MCF7 and HepG2 cells. Gap junction 
activity is correlated to the percentage of calcein-positive recipient cells in (D) 
parental MCF7 cells, (E) MCF7 cells stably transfected with hepaCAM, 
(F) HepG2 cells stably transfected with the pcDNA6B/V5-His empty vector 
and (G) HepG2 cells stably transfected with hepaCAM. The results presented 
are representative of two independent experiments with similar results. 
(H) Connexin 43 expression in hepaCAM-expressing cancer cells. Cell lysates 
were prepared from control and hepaCAM-expressing MCF7, HepG2 and 
U373 MG cells. 50 μg of cell lysates were subjected to western blot analysis 
using connexin 43 antibody. GAPDH was used as a loading control. The result 
presented is a representative experiment of two independent experiments with 
similar results.  
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3.2 hepaCAM expression promotes cell death by anoikis 
The previously published studies on hepaCAM have mainly focused on its 
functions in inhibiting proliferation and mediating cell-ECM adhesion and 
migration. We wanted to investigate whether hepaCAM has unpublished roles 
in cell-cell adhesion and cell survival. As discussed briefly in the introduction, 
cellular adhesion to the ECM mediated by CAMs transmits cell survival 
signals. When anchorage-dependent cells are detached from the ECM, anoikis, 
a form of programmed cell death, is induced. Thus, anoikis is a mechanism to 
maintain normal tissue organisation and prevent dysplasia by eliminating cells 
that have managed to escape from their environment (Frisch and Screaton, 
2001). On the other hand, tumour cells tend to form multicellular aggregates 
or spheroids in the absence of attachment to the ECM. The formation of 
aggregates when tumour cells are grown under anchorage-independent 
conditions is proposed to suppress anoikis, facilitating their survival and 
metastasis (Kang et al., 2007; Zhang et al., 2004). 
Since hepaCAM expression in U373 MG cells targets connexin 43 to cell-cell 
contacts and promotes gap junction activity, we wanted to study whether it 
also influences anoikis and the aggregation of U373 MG cells into spheroids. 
Vector-transfected and WT hepaCAM-expressing U373 MG cells were 
detached into a single-cell suspension and cultured overnight on dishes coated 
with poly-HEMA, which will prevent attachment and create anchorage-
independent conditions. The sizes of the cellular aggregates formed were 
quantified by confocal microscopy (Figure 22), and the percentage anoikis 
was determined by annexin V/7-AAD staining (Figure 23). Interestingly, WT 
hepaCAM-expressing U373 MG cells tended to form significantly smaller 
 100 
aggregates compared to vector-transfected U373 MG cells (Figure 22A, B). In 
addition, WT hepaCAM-expressing U373 MG cells grown under anchorage-
independent conditions had a higher rate of apoptosis at 22.0% (7.1% higher 
than the baseline apoptosis of 14.9% in the monolayer culture), compared to 
vector-transfected U373 MG cells at 11.9% (4.5% higher than the baseline 
apoptosis of 7.4% in the monolayer culture) (Figure 23), suggesting that 







Figure 22. hepaCAM-expressing U373 MG cells form smaller aggregates 
when grown under anchorage-independent conditions. Vector-transfected 
and wild-type hepaCAM-expressing U373 MG cells were stained with 
calcein-AM, detached into a single-cell suspension and seeded onto poly-
HEMA-coated culture dishes. After culturing overnight, the aggregates were 
visualised by confocal microscopy under a 10× objective. (A) Confocal z-
stacks of the scans were reconstructed. The images presented here are 
representative of images taken from at least six different fields. (B) The 
volume of each aggregate was determined for vector-transfected (n = 14) and 
wild-type hepaCAM-expressing (n = 26) U373 MG cells. ** p < 0.01 as 







Figure 23. hepaCAM-expressing U373 MG cells are more susceptible to 
anoikis when grown under anchorage-independent conditions. Vector-
transfected and wild-type hepaCAM-expressing U373 MG cells were 
detached into a single-cell suspension and seeded onto poly-HEMA-coated 
culture dishes. After culturing overnight, the aggregates were harvested, 
dissociated and assayed for anoikis by annexin V/7-AAD staining. Cells 
grown as monolayer cultures were included as controls to determine the 
baseline apoptosis. (A) The percentage total apoptosis in vector-transfected 
U373 MG cells grown as a monolayer is 7.4%. (B) The percentage total 
apoptosis in vector-transfected U373 MG cells grown under anchorage-
independent conditions is 11.9%. (C) The percentage total apoptosis in wild-
type hepaCAM-expressing U373 MG cells grown as a monolayer is 14.9%. 
(D) The percentage total apoptosis in wild-type hepaCAM-expressing 
U373 MG cells grown under anchorage-independent conditions is 22.0%. 
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3.3 hepaCAM signalling and proteolytic cleavage of the hepaCAM 
cytoplasmic domain 
This section discusses the experiments to study the signals that lead to 
hepaCAM cytoplasmic domain cleavage in cancer cells exogenously 
expressing hepaCAM. 
3.3.1. Mutations in hepaCAM affect cleavage of the hepaCAM 
cytoplasmic domain in U373 MG cells 
As mentioned in section 1.6.8, hepaCAM expressed exogenously in MCF7 
breast cancer cells undergoes proteolytic cleavage to generate a 25 kD 
fragment containing mainly the cytoplasmic domain (Zhang et al., 2010a). We 
wanted to study whether this phenomenon could also be observed in 
U373 MG glioblastoma cells stably transfected with WT hepaCAM. To detect 
the cleaved hepaCAM fragment by western blot, a custom-made antibody 
against the hepaCAM cytoplasmic domain was utilised. Western blot analysis 
showed that in addition to full-length hepaCAM at 75 kD, a band at 
approximately 25 kD could be detected in WT hepaCAM-expressing 
U373 MG cells. Since the 25 kD band was not detected in vector-transfected 
U373 MG cells, it indicates that it is specific for the cleaved hepaCAM 
fragment (Figure 24). Thus, the results suggest that proteolytic cleavage of the 
hepaCAM cytoplasmic domain is a ubiquitous event in the processing of 
hepaCAM in different cancer cell lines. 
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Figure 24. Mutations in the hepaCAM extracellular domain prevent 
proteolytic cleavage of the hepaCAM cytoplasmic domain in U373 MG 
cells. Cell lysates were prepared from U373 MG cells stably transfected with 
pcDNA3.1 vector, wild-type hepaCAM, hepaCAM-R92Q and hepaCAM-
R92W. 20 μg of cell lysates were subjected to western blot analysis. Full-
length hepaCAM was detected with an antibody against the hepaCAM 
extracellular domain. The 25 kD cleaved hepaCAM fragment was detected 
with an antibody against the hepaCAM cytoplasmic domain. GAPDH was 
used as a loading control. The result presented is a representative experiment 
of at least four independent experiments with similar results. 
 
 
Since we were also interested in studying the signalling mechanisms which 
lead to hepaCAM cytoplasmic domain cleavage, we next determined whether 
the R92Q and R92W mutations in hepaCAM had any effects on the levels of 
the 25 kD cleaved hepaCAM fragment. Interestingly, the cleaved hepaCAM 
cytoplasmic domain was not detected in cells expressing hepaCAM-R92Q or 
hepaCAM-R92W (Figure 24). As these mutations occur in the hepaCAM 
extracellular domain, it suggested that signalling through the extracellular 
domain leads to proteolytic cleavage of the cytoplasmic domain. 
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3.3.2. Treatment with an antibody against the hepaCAM extracellular 
domain blocks cleavage of the hepaCAM cytoplasmic domain  
To test the hypothesis that signalling through the hepaCAM extracellular 
domain leads to proteolytic cleavage of the cytoplasmic domain, we next 
determined the levels of the 25 kD cleaved fragment in WT hepaCAM-
expressing U373 MG cells upon overnight treatment with an antibody against 
the hepaCAM extracellular domain. As observed in Figure 25, the levels of 
the cleaved hepaCAM cytoplasmic domain fragment were markedly reduced 
in cells treated with the hepaCAM antibody, compared to cells treated with the 
IgG control, indicating that the binding of the antibody to the hepaCAM 
extracellular domain inhibits proteolytic cleavage of the hepaCAM 
cytoplasmic domain in U373 MG cells. Thus, this antibody likely has 
antagonistic activities against the functions of hepaCAM. 
The levels of the 25 kD cleaved hepaCAM fragment were also determined in 
in hepaCAM-expressing MCF7 and HepG2 cells upon overnight treatment 
with an antibody against the hepaCAM extracellular domain. Proteolytic 
cleavage of the hepaCAM cytoplasmic domain was observed in control IgG-
treated MCF7 and HepG2 cells. However, upon treatment with the hepaCAM 
antibody, hepaCAM cytoplasmic domain cleavage was significantly inhibited 
in both MCF7 and HepG2 cells (Figure 26), similar to the observations in 
U373 MG cells and confirming the ubiquity of hepaCAM cytoplasmic domain 
processing in diverse cancer cell lines. The results also suggested a possibility 
that the signalling mechanisms leading to hepaCAM proteolytic cleavage are 
similar across different cell lines. 
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It should also be noted that the inhibition of hepaCAM cytoplasmic domain 
proteolytic cleavage occurred at comparable levels when cells were treated 





Figure 25. Treatment of hepaCAM-expressing U373 MG cells with an 
antibody against the hepaCAM extracellular domain prevents proteolytic 
cleavage of the hepaCAM cytoplasmic domain. Wild-type hepaCAM-
expressing U373 MG cells were treated overnight with antibody against the 
hepaCAM extracellular domain in soluble form (10 μg/ml). Cells were also 
treated with PBS or the isotype mouse IgG1 as controls. The next day, cells 
were lysed and 20 μg of cell lysates were subjected to western blot analysis. 
Full-length hepaCAM (75 kD) and the cleaved hepaCAM fragment (25 kD) 
were detected using an antibody against the FLAG-tag on the hepaCAM 
cytoplasmic domain. GAPDH was used as a loading control. The result 








Figure 26. Treatment of hepaCAM-expressing MCF7 and HepG2 cells 
with an antibody against the hepaCAM extracellular domain prevents 
proteolytic cleavage of the hepaCAM cytoplasmic domain. MCF7 and 
HepG2 cells were stably transfected with hepaCAM and treated overnight 
with antibody against the hepaCAM extracellular domain in soluble form (10 
μg/ml). Cells were also treated with the isotype mouse IgG1 as a control. The 
next day, cells were lysed and 20 μg of cell lysates were subjected to western 
blot analysis using antibodies against the V5-tag on the hepaCAM 
cytoplasmic domain. GAPDH was used as a loading control. The result 





3.3.3. Connexin 43 knockdown does not affect the cleavage of the 
hepaCAM cytoplasmic domain in U373 MG cells 
As shown in section 3.1, the extracellular domain of hepaCAM interacts with 
connexin 43. Since treatment of U373 MG cells with an antibody against the 
hepaCAM extracellular domain inhibited hepaCAM cytoplasmic domain 
cleavage and concomitantly downregulated connexin 43 expression, we 
wanted to investigate the possibility that these two events may be 
interconnected in U373 MG cells. Such a possibility was also suggested by the 
observation that hepaCAM cytoplasmic domain cleavage is inhibited in the 
mutant hepaCAM-expressing U373 MG cells which also have reduced 
connexin 43 expression. To determine whether connexin 43 expression had 
any effects on hepaCAM cytoplasmic domain cleavage, silencing of connexin 
43 expression was performed in WT hepaCAM-expressing U373 MG cells by 
transfection with connexin 43 siRNA, and the levels of the 25 kD cleaved 
hepaCAM fragment were evaluated 48 h post-transfection by western blot.  
 
Figure 27. Silencing of connexin 43 does not affect proteolytic cleavage of 
the hepaCAM cytoplasmic domain in U373 MG cells. Wild-type 
hepaCAM-expressing U373 MG cells were transfected with 5 nM connexin 
43 siRNA or scrambled siRNA and lysed 48 h post-transfection. 20 μg of cell 
lysates were subjected to western blot analysis using an antibody against the 
hepaCAM cytoplasmic domain to detect the 25 kD cleaved hepaCAM 
fragment, and connexin 43 antibody. GAPDH was used as a loading control. 
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Silencing of connexin 43 did not affect hepaCAM cytoplasmic domain 
cleavage, as the levels of 25 kD cleaved hepaCAM fragment were comparable 
in scrambled and connexin 43 siRNA-transfected cells (Figure 27). The results 
thus indicated that while neutralisation of hepaCAM with an antibody both 
inhibited hepaCAM cytoplasmic domain cleavage and downregulated 
connexin 43 expression, these two downstream events were regulated 
independently of each other in U373 MG cells. 
3.3.4. The cleaved hepaCAM cytoplasmic domain fragment is localised 
to the endomembrane system and the nucleus 
To further understand the functions of the cleaved hepaCAM cytoplasmic 
domain fragment, subcellular fractionation was performed to determine its 
localisation in hepaCAM-expressing cells. The cytoplasmic, membrane 
(containing the contents of the plasma, mitochondria, ER and Golgi 
membranes), soluble nuclear and chromatin-bound nuclear fractions were 
isolated from hepaCAM-expressing HepG2 cells and analysed by western blot 






Figure 28. The cleaved hepaCAM cytoplasmic domain fragment is 
localised to the membrane and soluble nuclear fractions. HepG2 cells 
stably transfected with hepaCAM were subjected to subcellular fractionation 
to isolate the cytoplasmic, membrane, soluble nuclear and chromatin-bound 
nuclear fractions. The membrane fraction contains the contents of the plasma, 
mitochondria, ER and Golgi membranes. 20 μg of each fraction was subjected 
to western blot analysis. Full-length hepaCAM and the cleaved hepaCAM 
fragment were detected with an antibody against the hepaCAM cytoplasmic 
domain. GAPDH and HDAC2 were used as loading controls for the 




As shown in Figure 28, full-length hepaCAM was detected in all fractions, 
with the highest levels found in the membrane fraction. The 25 kD cleaved 
hepaCAM fragment was detected in both the membrane and soluble nuclear 
fractions. Similar localisation of full-length hepaCAM and the cleaved 
hepaCAM fragment was also observed in U373 MG cells (data not shown). 
The presence of the cleaved hepaCAM fragment in the membrane fraction 
suggests two possibilities: (1) the cytoplasmic domain of hepaCAM may be 
cleaved post-translationally by proteases in the ER and Golgi compartments 
while it is trafficked to the plasma membrane; (2) hepaCAM may undergo 
proteolytic cleavage in the endosomal vesicles upon its internalisation. 
Furthermore, its presence in the soluble nuclear fraction and its absence in the 
chromatin-bound nuclear fraction indicate that it may have functions in the 
regulation of gene expression but does not directly bind to DNA sequences as 
a transcription factor. The origin of the cleaved hepaCAM fragment in the 
soluble nuclear fraction is not known at this point, as full-length hepaCAM 
could also be detected in the same fraction. Hence, it could have arisen from 
its translocation to the nucleus or proteolytic cleavage of hepaCAM present in 
the nucleus itself. 
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3.3.5. hepaCAM undergoes proteolytic cleavage upon binding to the 
integrin ligand fibronectin 
The proteolytic cleavage of the hepaCAM cytoplasmic domain was inhibited 
by the R92Q and R92W mutations in the hepaCAM extracellular domain, and 
by the neutralising antibody which also binds to the hepaCAM extracellular 
domain. These two observations led us to postulate that the binding of 
hepaCAM to an extracellular ligand provides the signal for the cleavage of the 
cytoplasmic domain. 
Expression of hepaCAM has been previously shown to increase cell adhesion 
and spreading on the ECM component fibronectin in the three cancer cell 
lines, HepG2, MCF7 and U373 MG (Lee et al., 2009; Moh et al., 2005a; Moh 
et al., 2005b). Since proteolytic cleavage of the hepaCAM cytoplasmic 
domain was also observed in these three cell lines, and was similarly inhibited 
by the antibody against the hepaCAM extracellular domain, we hypothesised 
that the interaction of hepaCAM with fibronectin may lead to proteolytic 
cleavage of the hepaCAM cytoplasmic domain. To verify the interaction of 
hepaCAM with fibronectin, the binding of fluorescently labelled fibronectin to 
WT hepaCAM-expressing U373 MG cells was measured by flow cytometry. 
As shown in Figure 29, binding to fibronectin was observed in 5.7% of vector-
transfected U373 MG cells and was increased to 22.0% for WT-hepaCAM-
expressing cells. These results confirmed that hepaCAM interacts with 





Figure 29. hepaCAM binds to fibronectin. U373 MG cells stably 
transfected with pcDNA3.1 vector or wild-type hepaCAM were dissociated 
and incubated with fluorescently labelled fibronectin (50 μg/ml) for 15 min, 
washed and analysed by flow cytometry. Indicated are the percentages of cells 
bound to fluorescently labelled fibronectin as compared to the background 
signal. The results presented are representative of four independent 
experiments with similar results. 
 
To test the hypothesis that binding to the integrin ligand fibronectin induces 
proteolytic cleavage of the hepaCAM cytoplasmic domain, WT hepaCAM-
expressing U373 MG cells were detached from a cell culture flask and seeded 
onto fibronectin-coated plates in a short time-course experiment of up to 60 
min. As a control, cells were also seeded onto plates coated with the non-
integrin ligand poly-L-lysine. In contrast to ECM proteins such as fibronectin, 
poly-L-lysine promotes cell attachment non-specifically and does not promote 
morphological spreading of cells (Akiyama, 2002). After allowing the cells to 
attach, they were harvested at the time-points 10, 30 and 60 min and western 
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blot analysis was performed to determine the levels of the 25 kD cleaved 
hepaCAM fragment upon adhesion to fibronectin (Figure 30). 
  
 
Figure 30. The hepaCAM cytoplasmic domain is proteolytically cleaved 
upon adhesion of hepaCAM-expressing U373 MG cells on fibronectin. 
U373 MG cells stably transfected with wild-type hepaCAM were detached 
and allowed to adhere to fibronectin-coated plates (FN). Plates coated with 
poly-L-lysine (P), a non-integrin ligand, were included as controls. An aliquot 
of the detached cells was retained as a control for time-point 0. At the 
respective time-points (10, 30 and 60 min), all cells were harvested and lysed. 
20 μg of cell lysates were subjected to western blot analysis using an HRP-
conjugated FLAG antibody to detect the FLAG-tag on the hepaCAM 
cytoplasmic domain. The result presented is a representative experiment of 
three independent experiments with similar results. 
 
As shown in Figure 30, there was increased proteolytic cleavage of the 
hepaCAM cytoplasmic domain in cells adhered to the fibronectin-coated 
plates compared to cells adhered to the poly-L-lysine control at 10 and 30 min, 
suggesting that integrin-mediated adhesion of cells to fibronectin induces 
hepaCAM cleavage. The gradual increase in hepaCAM proteolytic cleavage 
across time in cells adhered to the poly-L-lysine could be due to the eventual 
secretion of ECM proteins by U373 MG cells themselves. 
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3.3.6. hepaCAM is internalised upon adhesion and spreading of cells on 
fibronectin 
In U373 MG cells, hepaCAM can be detected in intracellular punctuate 
structures which suggested its presence in vesicles of the endomembrane 
system (Figure 6). Furthermore, subcellular fractionation showed that the 
cleaved hepaCAM fragment was detected in the membrane fraction, which 
contains components of the endomembrane system (Figure 28). Thus, we 
hypothesised that hepaCAM may be internalised upon the adhesion and 
spreading of cells on fibronectin, leading to its proteolytic cleavage. 
We first determined the subcellular localisation of hepaCAM in well-spread 
U373 MG cells grown on untreated cell culture plates. Cells were co-stained 
with the organelle markers: early endosome antigen 1 (EEA1), protein 
disulfide isomerase (PDI) and estrogen receptor-binding fragment-associated 
gene 9 (EBAG9, also known as RCAS1), which are markers for the 




Figure 31. hepaCAM is localised in the early endosomes. U373 MG cells stably transfected with wild-type hepaCAM were stained with 
antibodies against the hepaCAM cytoplasmic domain (green) and one of the indicated organelle markers (red). The organelle markers were 
EEA1 (early endosomes), PDI (endoplasmic reticulum) and EBAG9 (Golgi apparatus) (next page). Co-localisation is indicated by yellow 
fluorescence. hepaCAM staining co-localised with EEA1 is shown by white arrows in the inset. Nuclei were stained with DAPI (blue). Cells 
were visualised by confocal microscopy under a 60× objective. The images presented here are representative of images taken from at least six 










Figure 31 (continued). hepaCAM is localised in the early endosomes. U373 MG cells stably transfected with wild-type hepaCAM were 
stained with antibodies against the hepaCAM cytoplasmic domain (green) and one of the indicated organelle markers (red). The organelle 
markers were EEA1 (early endosomes) (previous page), PDI (endoplasmic reticulum) (previous page) and EBAG9 (Golgi apparatus). Co-
localisation is indicated by yellow fluorescence. hepaCAM staining co-localised with EEA1 is shown by white arrows in the inset. Nuclei were 
stained with DAPI (blue). Cells were visualised by confocal microscopy under a 60× objective. The images presented here are representative of 
images taken from at least six different fields. Scale bar: 10 µm. 
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Immunofluorescent staining showed a partial co-localisation of hepaCAM 
with EEA1 in the early endosomes and no significant co-localisation of 
hepaCAM with PDI in the ER and with EBAG9 in the Golgi apparatus (Figure 
31). In addition, there were intracellular punctuate structures containing 
hepaCAM but not co-stained with EEA1, and we postulate these may be 
staining for hepaCAM in secretory vesicles and/or endosomes at later stages. 
The results suggested that hepaCAM in untreated U373 MG cells undergoes 
internalisation as part of its normal turnover or signal transduction, and we 
hypothesise that this occurs prior to proteolytic cleavage of the hepaCAM 
cytoplasmic domain. 
Since integrin-mediated adhesion of cells to fibronectin induces cleavage of 
the hepaCAM cytoplasmic domain, we wanted to determine whether this also 
induces the internalisation of hepaCAM. WT hepaCAM-expressing U373 MG 
cells were detached from a cell culture flask and seeded onto fibronectin-
coated and poly-L-lysine-coated culture plates. Cells were allowed to adhere 
to the plates for 1 and 7 h before they were fixed and stained for hepaCAM 






Figure 32. hepaCAM is internalised upon the adhesion and spreading of 
hepaCAM-expressing U373 MG cells on fibronectin. U373 MG cells stably 
transfected with pcDNA3.1 vector or wild-type hepaCAM were detached and 
allowed to adhere to fibronectin-coated plates. Plates coated with poly-L-
lysine, a non-integrin ligand, were included as a control. After 1 and 7 h, 
unattached or loosely adherent cells were washed away, and attached cells 
were fixed and stained with antibodies against the hepaCAM cytoplasmic 
domain (green) and EEA1 (red). Co-localisation of hepaCAM and EEA1 is 
indicated by yellow fluorescence. Nuclei were stained with DAPI (blue). Cells 
were visualised by confocal microscopy under a 60× objective and confocal z-
stacks of the scans were reconstructed. The images presented here are 





As shown in Figure 32, upon the adhesion and spreading of cells on 
fibronectin for 1 h, there was significant co-localisation of hepaCAM with 
EEA1, indicating an internalisation of hepaCAM. The co-localisation 
persisted when cells were incubated for 7 h. In contrast, there was minimal co-
localisation of hepaCAM with EEA1 in cells adhered to poly-L-lysine at 1 and 
7 h. Furthermore, cells adhered to poly-L-lysine did not appear 
morphologically well-spread compared to cells adhered to fibronectin. Thus, 
the results suggested that hepaCAM is internalised upon integrin-mediated 
adhesion to and spreading of cells on fibronectin, and this concomitantly 
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CHAPTER 4 DISCUSSION 
4.1. Interaction of hepaCAM with connexin 43 
hepaCAM has been previously shown to interact with the membrane protein 
MLC1 and the chloride channel ClC-2 at the cell-cell junctions of astrocytes 
(Jeworutzki et al., 2012; Lopez-Hernandez et al., 2011a). In this present study, 
co-localisation and co-IP assays revealed a novel physical interaction of 
hepaCAM with the gap junction protein connexin 43 at cell-cell junctions of 
U373 MG human glioblastoma cells of astrocytic origin (Figure 33A). This 
interaction is not entirely unexpected, as MLC1 has been previously found to 
partially co-localise with connexin 43 at the astrocytic junctions (Duarri et al., 
2011). The hepaCAM-connexin 43 interaction is also the first interaction of 
hepaCAM with a junctional protein to be observed in cancer cells. In MCF7 
human breast cancer cells, no physical interaction of hepaCAM with the 
adherens junction protein E-cadherin was observed in co-IP assays, although 
the two proteins appeared to co-localise (Moh et al., 2005b). 
It was observed that the R92Q and R92W mutations which occur in the 
extracellular domain of hepaCAM, and the antibody which binds to the 
hepaCAM extracellular domain both disrupt the interaction of hepaCAM with 
connexin 43 at cell-cell contacts (Figure 33B, C). This suggested that the 
interaction of hepaCAM and connexin 43 occurs via the hepaCAM 
extracellular domain. The hepaCAM extracellular domain, specifically the 
first Ig-like domain, has been previously shown to be essential in its 
interaction with the lipid raft protein caveolin-1 (Moh et al., 2009a). Since the 
R92Q and R92W mutations in hepaCAM occur in the first Ig-like domain, we 
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postulate that the interaction of hepaCAM with connexin 43 also occurs via 
this domain. The association of hepaCAM with F-actin, on the other hand, was 
suggested to be dependent on its cytoplasmic domain, but require an intact 
hepaCAM containing the extracellular domain (Moh et al., 2009b). As 
discussed in section 1.2.1, Ig-CAMs can establish heterophilic cis-interactions 
with other transmembrane proteins, as well as interact with cytoskeletal 
proteins and adaptor proteins. Thus similar to other Ig-CAMs, hepaCAM 
exhibits cis-interactions with the transmembrane proteins connexin 43 and 
caveolin-1 via its extracellular domain and associates with the actin 
cytoskeleton via its cytoplasmic domain. 
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Figure 33. Schematic depiction of hepaCAM activities in U373 MG cells. 
(A) hepaCAM associates with connexin 43 at cell-cell contacts. (B) The R92Q 
and R92W mutations in the hepaCAM extracellular domain prevent 
association of hepaCAM with connexin 43 at cell-cell contacts. (C) Treatment 
of cells with antibody against the hepaCAM extracellular domain prevents 
association of hepaCAM with connexin 43 at cell-cell contacts and 
downregulates cell surface expression of connexin 43. (D) The hepaCAM 
cytoplasmic domain undergoes proteolytic cleavage under normal culture 
conditions or upon adhesion to the integrin ligand fibronectin. (E) The R92Q 
and R92W mutations in the hepaCAM extracellular domain block proteolytic 
cleavage of the cytoplasmic domain. (F) Treatment of cells with antibody 
against the hepaCAM extracellular domain blocks proteolytic cleavage of the 
cytoplasmic domain. 
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As shown by co-IP assays without prior cross-linking of proteins, connexin 43 
was weakly co-immunoprecipitated with hepaCAM-R92Q or hepaCAM-
R92W, compared to WT hepaCAM. However upon cross-linking, 
connexin 43 could be co-immunoprecipitated effectively with WT hepaCAM 
and mutant hepaCAM. This suggested that the binding site of hepaCAM to 
connexin 43 involves arginine (residue 92) in the first Ig-like domain, and that 
the R92Q and R92W mutations in hepaCAM both reduce the stability of its 
interaction with connexin 43. In the study by Lopez-Hernandez et al. (2011b), 
split-TEV assays showed that hepaCAM-R92Q had a decrease in its ability to 
hetero-oligomerise with MLC1, while hepaCAM-R92W still retained the 
ability to oligomerise with MLC1 at similar levels as WT hepaCAM. Thus, 
the R92Q and R92W mutations in hepaCAM appear to have differing effects 
on its interaction with connexin 43 and MLC1. For the R92Q mutation, the 
positively-charged (or basic) arginine is mutated to the polar uncharged 
glutamine, while for the R92W mutation, arginine is mutated to the non-polar 
tryptophan, which has a large hydrophobic side chain. The chemical bonds 
underlying hepaCAM’s interactions with connexin 43 and MLC1 may be 
different, and hence the mutations may affect the binding affinity differently. 
It would be interesting to determine whether the other MLC-causing mutations 
in hepaCAM also affect its interaction with connexin 43, and this will also aid 
in further delineating the hepaCAM residues involved in the binding site. It 
would also be interesting to determine how the MLC-causing mutations in 
hepaCAM, including R92Q and R92W, affect its interaction with caveolin-1. 
The cytoplasmic tail on the C-terminal end of connexin 43 contains several 
protein-protein interaction motifs, and has been shown to interact with various 
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proteins including the tight junction protein ZO-1 (Giepmans, 2004, 2006). As 
our findings indicate that it is the extracellular domain of hepaCAM which 
interacts with connexin 43, it is likely that this cis-interaction involves the 
extracellular loops of connexin 43. The docking of two apposing connexons to 
form a gap junction channel is dependent on the trans-interactions of the 
extracellular loops of connexins (Segretain and Falk, 2004). However, not 
much is currently known about the cis-interactions of the extracellular loops of 
connexin 43 with other proteins.  
Although we have shown a physical interaction of hepaCAM and connexin 43 
by co-IP assays, it is not completely known at this point whether the 
interaction is direct or indirect. While hepaCAM has also been shown to 
interact with caveolin-1 by co-IP assays, sequence analysis failed to identify 
consensus caveolin-binding motifs in hepaCAM (Moh et al., 2009a), raising 
the possibility that its interaction with caveolin-1 may be indirect. Thus, it still 
remains an open question whether hepaCAM interacts with connexin 43 as 
part of a complex containing other proteins. Since hepaCAM interacts with 
MLC1 and MLC1 partially co-localises with connexin 43, we also tried to 
determine MLC1 expression in vector-transfected and WT hepaCAM-
expressing U373 MG cells by western blot analysis. However, despite using 
an anti-MLC1 antiserum (Lopez-Hernandez et al., 2011a) and two different 
commercial anti-MLC1 polyclonal antibodies, multiple non-specific bands 
were obtained and no distinct band for MLC1 was observed at the expected 
size of 41 kD (data not shown). As MLC1 could not be unambiguously 
detected in U373 MG cells, this aspect of the study was not further pursued. 
  126 
4.2. hepaCAM is involved in the targeting of connexin 43 to cell-cell 
contacts  
An aberrant localisation of connexin 43 in the cytoplasm of cancer cells 
instead of the cell membrane has been observed in chemically-induced 
tumours and the invasive parts of carcinomas, suggesting this may be a 
general phenomenon in tumourigenesis. The mechanisms leading to the 
aberrant localisation of connexin 43 are not completely understood (Mesnil et 
al., 2005). In some cases, the cytoplasmic localisation of connexin 43 has been 
attributed to its impaired trafficking to the membrane, resulting in a loss of 
GJIC (Govindarajan et al., 2002). In other cases, the intracellular 
accumulation of connexin 43 has been reported to be due to its internalisation 
in endosomes (Guan and Ruch, 1996; Mograbi et al., 2003).  
In this study, we observed an intracellular accumulation of connexin 43 in 
U373 MG cells, with little staining at the cell membrane, similar to previous 
studies in glioblastoma cells (Cottin et al., 2008). Exogenous expression of 
WT hepaCAM in U373 MG cells caused a relocalisation of connexin 43 to the 
cell membrane at sites of cell-cell contacts, as well as increased its protein 
expression. This parallels previous observations that knockdown of hepaCAM 
expression in primary rat astrocytes led to an intracellular accumulation and 
reduced expression of MLC1 on the plasma membrane at cell-cell junctions 
(Capdevila-Nortes et al., 2013). Similarly, co-expression of hepaCAM with 
ClC-2 in HeLa cells led to a re-distribution of ClC-2 at cell-cell contacts 
(Jeworutzki et al., 2012). These findings taken together imply that hepaCAM 
plays a general role in the targeting of its interacting partners to cell-cell 
contacts. It should be noted that Jeworutzki et al. (2012) had reported no 
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changes in connexin 43 expression and localisation upon overexpression of 
hepaCAM in rat astrocytes; however, this may be explained by the fact that 
these astrocytes already express endogenous hepaCAM and some connexin 43 
could be detected at astrocyte processes even without overexpression of 
hepaCAM.  
The R92Q and R92W mutations in hepaCAM inhibited the functions of 
hepaCAM in targeting connexin 43 to the cellular junctions of U373 MG cells. 
These mutants of hepaCAM also showed a reduced localisation themselves at 
cellular junctions and tended to co-localise with connexin 43 intracellularly. 
This correlates with previous observations that MLC1 and ClC-2 in rat 
astrocytes are mis-localised when co-expressed with hepaCAM-R92Q, 
hepaCAM-R92W or other MLC-causing mutants of hepaCAM. These 
hepaCAM mutants, MLC1 and ClC-2 had a diffused intracellular localisation 
with partial enrichment in the plasma membrane, but not particularly at 
cellular junctions (Jeworutzki et al., 2012; Lopez-Hernandez et al., 2011a). 
Thus, it can be implied that MLC-causing mutations inhibit the general 
activities of hepaCAM in targeting itself and its interacting proteins to cell-cell 
contacts. 
The silencing of connexin 43 in WT hepaCAM-expressing U373 MG cells did 
not affect hepaCAM localisation at cell-cell contacts. Similarly, hepaCAM 
localisation in astrocyte-astrocyte processes was not affected in ClC-2 
knockout mice (Hoegg-Beiler et al., 2014) or by the knockdown of MLC1 
(Lopez-Hernandez et al., 2011b), suggesting that hepaCAM is not obligatorily 
associated with MLC1 and ClC-2. Hence, the localisation of hepaCAM at the 
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cell-cell contacts of U373 MG cells is independent of its interaction with 
connexin 43. 
4.3. hepaCAM increases the stability of connexin 43  
Connexin 43 is known to undergo rapid turnover. In this study, connexin 43 
expression is increased in U373 MG and HEK293T cells expressing WT 
hepaCAM, not due to an increase in its transcription, but due to its slower rate 
of turnover. The increased stability of connexin 43 protein is due to its 
interaction with hepaCAM, as treatment of cells with an antibody against the 
hepaCAM extracellular domain disrupts this interaction and causes a 
downregulation in connexin 43 expression. Similarly, the R92Q and R92W 
mutations in hepaCAM, which lead to a weaker interaction with connexin 43, 
did not enhance connexin 43 protein levels in U373 MG cells, unlike WT 
hepaCAM. These results parallel previous observations that the interaction of 
hepaCAM with MLC1 in rat astrocytes increases the protein stability of 
MLC1 (Capdevila-Nortes et al., 2013).  
4.4. Functional significance of the interaction of hepaCAM with 
connexin 43 in U373 MG cells 
4.4.1. hepaCAM increases connexin 43-mediated gap junction activity  
After characterisation of the hepaCAM-connexin 43 interaction, we 
subsequently found that hepaCAM caused a two-fold increase in gap junction 
activity in U373 MG cells. Since the R92Q and R92W mutations in 
hepaCAM, as well as treatment of hepaCAM-expressing cells with an 
antibody against the hepaCAM extracellular domain both disrupted hepaCAM 
localisation at cellular junctions, it suggested that 
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gap junction assembly and turnover. Thus, the increased gap junction activity 
in hepaCAM-expressing U373 MG cells is due to a slower rate of gap junction 
and connexin 43 turnover, resulting in more functional gap junction plaques 
on the cell surface. It should be noted that some gap junction activity could 
still be observed in the vector-transfected U373 MG cells despite a 
predominant intracellular accumulation of connexin 43. Cottin et al. (2008) 
had also shown that functional gap junction transfer could still occur in 
glioblastoma cell lines which had only a few gap junction plaques on the cell 
surface and mainly intracellular localisation of connexin 43. However, our 
findings indicate that hepaCAM expression in U373 MG cells significantly 
enhances gap junction transfer, implying a role of hepaCAM in promoting 
cell-cell communication in glioblastoma cells. 
Presently, we also show that the exogenous expression of hepaCAM 
specifically increases gap junction activity mediated by connexin 43, as 
hepaCAM expression did not increase gap junction activity in cell lines which 
lack endogenous connexin 43 expression, MCF7 and HepG2. It would also be 
ideal to repeat the calcein-AM transfer assay using hepaCAM-expressing 
U373 MG cells in which connexin 43 expression had been silenced to further 
substantiate our findings. 
Several studies have reported an involvement of other CAMs in the interaction 
with connexin 43 at gap junctions. For example, connexin 43 has been shown 
to interact with the tight junction protein ZO-1. Although the functional 
significance of this interaction is not completely understood, it suggests that 
there is cross-talk between tight junctions and gap junctions (Dbouk et al., 
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2009; Giepmans, 2004). Connexin 43 is also known to interact with the 
adherens junction proteins N-cadherin, β-catenin, p120 and α-catenin, 
suggesting that there may also be cross-talk between gap junctions and 
adherens junctions (Giepmans, 2004, 2006). In a study by Musil et al. (1990), 
transfection of L-CAM induced the formation of gap junctions in cells which 
expressed connexin 43 but were otherwise GJIC-deficient. Interestingly, 
antibodies against L-CAM led to the disassembly of gap junctions, which 
parallels our findings on hepaCAM in U373 MG cells. In addition to 
interacting with CAMs, connexin 43 has also been shown to interact with 
caveolin-1 and caveolin-2, which may regulate GJIC in keratinocytes 
(Langlois et al., 2008).  
A question that needs to be addressed is how the interaction with hepaCAM 
increases the stability of connexin 43 and its gap junctions in U373 MG cells. 
As discussed in section 1.7.1, gap junctions are disassembled into individual 
connexin 43 proteins, which are subsequently degraded by both lysosomal and 
proteasomal pathways. It would be worthwhile to determine the pathway in 
which connexin 43 is degraded in U373 MG cells to further understand the 
mechanisms by which hepaCAM slows down connexin 43 turnover.  
4.4.2. Connexin 43-independent functions of hepaCAM in tumour 
suppression 
Since hepaCAM interacts with connexin 43 in U373 MG cells, we also 
investigated the influence of connexin 43 on the previously published 
functions of hepaCAM in cell adhesion, migration and proliferation. Although 
connexin 43 itself has been reported to mediate cell adhesion and migration 
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(Cotrina et al., 2008; Elias et al., 2007; Lin et al., 2002), its silencing had no 
significant effects on the increased adhesion and reduced migration of 
hepaCAM-expressing U373 MG cells. As discussed in section 1.7.3.3, 
connexin 43 has also been shown to inhibit proliferation, but silencing of 
connexin 43 did not reverse the anti-proliferative effects of hepaCAM in 
U373 MG cells. Thus, these functions of hepaCAM in U373 MG cells are 
independent of connexin 43. 
4.4.3. A proposed mechanism of hepaCAM-mediated tumour 
suppression in U373 MG cells 
The loss of GJIC is frequently observed during tumourigenesis. While it was 
observed in this study that hepaCAM increases GJIC in U373 MG cells, it still 
remains to be elucidated how this contributes to tumour suppression, as the 
tumour suppressive properties of connexins by GJIC-dependent mechanisms 
are not completely understood. It could be that hepaCAM promotes GJIC-
mediated exchange of uncharacterised small molecules, which maintain 
homeostasis in normal healthy tissues as discussed in section 1.7.3.2. 
It should be noted that while hepaCAM expression in U373 MG cells targets 
connexin 43 to cell-cell contacts and promotes GJIC, it did not increase the 
size of cellular aggregates when the cells were cultured in suspension. It may 
be because there are different mechanisms in maintaining cell-cell adhesion 
when cells are attached to a matrix and when cells encounter anchorage-
independent conditions. Thus, we postulate that hepaCAM expression 
increases cell-ECM adhesion, as well as targets connexin 43 to cell-cell 
contacts to increase GJIC within a primary tumour, making it more difficult 
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for tumour cells to detach and disseminate during metastasis. On the other 
hand, when cells do manage to escape from a primary tumour, hepaCAM 
expression may confer a slightly increased sensitivity to anoikis and cause 
smaller cellular aggregates to form. It has been shown that tumour cells which 
formed aggregates when cultured in suspension had lower rates of apoptosis 
compared to single cells, and that the increased size of aggregates is correlated 
with increased survival, or resistance to anoikis (Valentinis et al., 1998; Zhang 
et al., 2004). 
4.5. Proteolytic cleavage of the hepaCAM cytoplasmic domain and 
internalisation of hepaCAM 
4.5.1. Functions of the cleaved hepaCAM cytoplasmic domain fragment 
The cytoplasmic domain of CAMs such as Ig-CAMs has been shown to 
undergo proteolytic cleavage, and the resulting cytoplasmic fragment is 
capable of signal transduction in the absence of the extracellular domain 
(Cavallaro and Dejana, 2011). It was previously shown that hepaCAM 
undergoes proteolytic cleavage when exogenously expressed in MCF7 cells, 
generating a fragment that consists mainly of the cytoplasmic domain with 
unknown biological functions (Zhang et al., 2010a). In this study, we further 
show that proteolytic cleavage of the hepaCAM cytoplasmic domain occurs in 
U373 MG (Figure 33D) and HepG2 cells, thus suggesting that it may be a 
ubiquitous event in the processing of hepaCAM in different human cancer cell 
lines. In addition, we show by subcellular fractionation that the cleaved 
hepaCAM fragment could be found in the nucleus, suggesting that proteolytic 
cleavage does not occur merely in hepaCAM protein turnover, but also has 
functions in regulating gene expression. However, the cleaved hepaCAM 
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fragment does not directly bind to DNA as a transcription factor since it was 
not detected in the chromatin-bound nuclear fraction. Thus, we postulate that 
the cleaved hepaCAM fragment may interact with other transcription factors 
instead, thereby activating and/or stabilising them. We also speculate that the 
cleaved hepaCAM fragment may be responsible for upregulating the 
expression of genes such as p53, p21 and p27, since hepaCAM expression was 
previously shown to increase their protein levels in MCF7 cells (Moh et al., 
2008). 
The notion of the cleaved cytoplasmic domain fragments of CAMs having 
functions in regulating gene expression is not novel. For example, the 
cytoplasmic fragment of L1, an Ig-CAM, is able to regulate the gene 
expression of β3 integrin, similar to the full-length L1 protein (Riedle et al., 
2009). The intracellular domain of epithelial cell adhesion molecule (EpCAM) 
has been shown to bind to and activate the promoters of the reprogramming 
factor genes OCT4, SOX2, NANOG, and c-MYC (Lin et al., 2012). Since the 
cytoplasmic domain is important in hepaCAM’s functions in inhibiting cell 
proliferation (Moh et al., 2008), it would be worthwhile to identify the 
proteins which interact with the cleaved hepaCAM fragment and their 
downstream signalling pathways to further understand the mechanisms of 
hepaCAM-mediated tumour suppression.  
Presently, we found that the cleaved hepaCAM fragment was not detected in 
U373 MG cells expressing hepaCAM with the MLC-causing mutations, R92Q 
and R92W (Figure 33E). It would be interesting to determine whether such a 
phenomenon is also observed in cells expressing the other MLC-causing 
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mutations. Although these mutations in hepaCAM have not been studied in 
cancer, our findings may have a wider implication in the understanding of 
hepaCAM processing in the disease MLC. The pathogenesis of MLC thus far 
has been attributed to changes in the interactions of hepaCAM with MLC1 
and ClC-2, thus leading to modifications in ClC-2 currents (Hoegg-Beiler et 
al., 2014). We speculate that differences in the cytoplasmic domain cleavage 
of the hepaCAM mutants may also contribute to the pathogenesis of MLC by 
affecting gene regulation. Thus, it would be worthwhile to determine whether 
proteolytic cleavage of the hepaCAM cytoplasmic domain also occurs in other 
cell types with endogenous hepaCAM expression, for example astrocytes and 
oligodendrocytes which are implicated in the etiology of MLC, and whether it 
is affected by MLC-causing mutations in hepaCAM. 
4.5.2. Signalling events leading to the internalisation of hepaCAM and 
the cleavage of its cytoplasmic domain 
It is interesting to note that proteolytic cleavage of the hepaCAM cytoplasmic 
domain in U373 MG cells was also inhibited by treatment with the antibody 
against the hepaCAM extracellular domain (Figure 33F). Since the antibody 
against the hepaCAM extracellular domain also disrupts cis-interactions with 
connexin 43 in U373 MG cells, we tested whether the silencing of connexin 
43 affects hepaCAM cytoplasmic domain cleavage. This was not the case, 
however, and led us to two different possibilities: cleavage of the hepaCAM 
cytoplasmic domain is induced by (1) the binding of the hepaCAM 
extracellular domain to an extracellular ligand or (2) the cis-interaction of 
hepaCAM with other proteins on the plasma membrane. Presently, we found 
that the binding of hepaCAM to the integrin ligand fibronectin increased 
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proteolytic cleavage of its cytoplasmic domain, compared to the non-integrin 
ligand poly-L-lysine. This suggested that cleavage of the hepaCAM 
cytoplasmic domain is promoted by the interaction of the hepaCAM 
extracellular domain with fibronectin. At this point, it is not completely 
understood whether the binding of hepaCAM to fibronectin is direct or 
indirect. It is not ruled out that hepaCAM may interact with other known 
fibronectin receptors such as integrins, and the expression of these adhesion 
receptors may be upregulated in hepaCAM-expressing cells, hence increasing 
the affinity of these cells to fibronectin. For example, the integrins α5β1 and 
αvβ3 are known to bind to the RGD motif on fibronectin (Danen et al., 2002; 
Wennerberg et al., 1996). The expression of these integrins and their 
interaction with hepaCAM should be further studied to elucidate the 
mechanisms by which hepaCAM promotes cell adhesion to fibronectin. 
While proteolytic cleavage of the hepaCAM cytoplasmic domain was initially 
inhibited in cells adhered to the non-integrin ligand poly-L-lysine at 10 and 30 
min, it gradually increased over time. It is surmised that this may be due to the 
eventual secretion of ECM proteins by U373 MG cells themselves on poly-L-
lysine-coated plates. The expression of fibronectin and other ECM proteins in 
U373 MG cells should be determined to further validate this supposition. 
Since hepaCAM expression also increased cell spreading on Matrigel (Moh et 
al., 2005b), a basement membrane preparation containing other ECM proteins 
such as laminin and collagen, it would be interesting to determine whether 
hepaCAM also increases the affinity of cells to these ECM proteins, and 
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whether this promotes proteolytic cleavage of the hepaCAM cytoplasmic 
domain. 
Although silencing of connexin 43 did not inhibit the proteolytic cleavage of 
the hepaCAM cytoplasmic domain, it still remains to be seen whether the cis-
interaction of hepaCAM with other proteins on the plasma membrane provides 
the signal for this phenomenon. We have discussed that the hepaCAM 
extracellular domain also interacts with caveolin-1, and it would be 
worthwhile to investigate whether the depletion of caveolin-1 affects 
hepaCAM cytoplasmic domain processing. 
It is still an open question whether the cleaved hepaCAM fragment found in 
the soluble nuclear fraction is due to its nuclear translocation or proteolytic 
cleavage of full-length hepaCAM that is present in the same fraction itself. 
Subcellular fractionation experiments showed that the cleaved hepaCAM 
fragment is also present in the membrane fraction, which contains the contents 
of the plasma membrane, mitochondria, ER, Golgi membranes and 
endosomes. Although the cellular location of hepaCAM proteolytic cleavage 
has not been identified yet, we postulate that it may occur upon its 
internalisation from the plasma membrane in the endosomal compartments. 
We have shown a partial co-localisation of hepaCAM with the early 
endosomal marker EEA1 in U373 MG cells under normal culture conditions, 
suggesting that hepaCAM on the plasma membrane is constitutively 
internalised in endosomes. Furthermore, upon adhesion of U373 MG cells to 
fibronectin, hepaCAM is internalised and a concomitant increase in hepaCAM 
cytoplasmic domain cleavage is observed, compared to cells adhered to poly-
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L-lysine. Thus, it is likely that internalisation of hepaCAM occurs prior to its 
proteolytic cleavage in the endosomes, and that the cleaved hepaCAM 
fragment subsequently translocates to the nucleus. Since hepaCAM is 
localised to lipid rafts/caveolae and associates with caveolin-1 (Moh et al., 
2009a), it is probable that hepaCAM is internalised by caveolin-1-mediated 
endocytosis. 
A question that needs to be addressed is why endocytosis of hepaCAM occurs 
upon integrin-mediated adhesion of cells to fibronectin. It is known that 
endocytosis of integrins constantly occurs during cell adhesion and migration, 
and its function is to recycle the integrins, rather than degrade them (Pellinen 
and Ivaska, 2006). Interference with the endocytosis and recycling of integrins 
can inhibit cell adhesion and motility (Proux-Gillardeaux et al., 2005; Roberts 
et al., 2001). In addition, it has been proposed that the endocytosis of integrins 
and the ECM proteins ligated to the integrins are important in ECM turnover 
and remodelling. For example, caveolin-1-dependent endocytosis of both β1 
integrin and its ligated fibronectin is important in fibronectin matrix turnover 
(Shi and Sottile, 2008). Thus, it is possible that hepaCAM may be 
endocytosed as part of ECM turnover and remodelling during cellular 
adhesion, and proteolytically cleaved as a means of signal transduction into 
the cell to provide information on its location, local environment and adhesive 
state, not unlike “outside-in signalling” mediated by integrins (discussed in 
section 1.2.2). 
Using inhibitors of calpain-1 and cathepsin-B, the study by Zhang et al. 
(2010a) had suggested the possible involvement of these cysteine proteases in 
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the cleavage of the hepaCAM cytoplasmic domain. However, the exact 
residue at which hepaCAM is proteolytically cleaved has not been elucidated 
yet. Calpain-1 is a calcium-dependent, non-lysosomal intracellular protease 
which cleaves a broad number of substrates but does not appear to recognise a 
specific amino acid sequence. It has been proposed that cleavage by calpain-1 
may be dependent on the higher order structural features of substrates 
(Cuerrier et al., 2005; Huang and Wang, 2001; Tompa et al., 2004). 
Cathepsin-B is a lysosomal protease and also has a broad specificity. Several 
studies have suggested that cathepsin-B has a preference for certain amino 
acids at specific positions of its substrates, but the understanding of its 
selectivity is not yet complete (Biniossek et al., 2011; Turk et al., 2012). Thus, 
further studies are required to determine the amino acid position at which 
hepaCAM is cleaved. One possible approach would involve purification of the 
cleaved hepaCAM fragment and N-terminal protein sequencing. 
4.6. Future work 
As discussed in section 4.5.1, it would be worthwhile to study the downstream 
signalling pathways of the cleaved hepaCAM cytoplasmic domain fragment to 
further understand the mechanisms of hepaCAM-mediated tumour 
suppression. Preliminary studies to transfect MCF7 and U373 MG cells with a 
construct for residues 260-416 of hepaCAM, which approximates the 
hepaCAM cytoplasmic domain, were unsuccessful as there was extensive cell 
death and low expression in surviving cells (data not shown). As this had been 
observed previously, it is likely that overexpression of the hepaCAM 
cytoplasmic domain alone leads to far-ranging effects on cell survival and 
death (Moh Mei Chung, personal communication). Thus, a possible option is 
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to clone the hepaCAM cytoplasmic domain into an expression vector with an 
inducible promoter. In this way, the downstream activities of the hepaCAM 
cytoplasmic domain can be studied in transfected cells upon induction of its 
expression. Alternatively, it may be worthwhile to raise an antibody which 
specifically recognises the cleaved hepaCAM fragment, but not full-length 
hepaCAM. For example in studying EpCAM signalling, Lin et al. (2012) 
utilised an antibody that recognises the soluble intracellular domain of 
EpCAM but not the full-length protein. Using either method, we can then 
further verify the nuclear translocation of the cleaved hepaCAM fragment by 
immunofluorescence staining. The effects of the hepaCAM cytoplasmic 
domain alone in mediating growth inhibition can also be further studied by 
proliferation and apoptosis assays, and the downstream effectors of hepaCAM 
cytoplasmic domain signalling can be identified by proteomics-based 
technologies. 
As previously published studies have utilised in vitro cell line models in 
studying the functions of hepaCAM, it may be worthwhile to perform 
xenografts in mouse models using control and hepaCAM-expressing cancer 
cells. Tumour growth and metastasis can be monitored in these xenograft 
models to better understand the functions of hepaCAM in a physiological 
setting. It is also interesting to note that while hepaCAM expression increased 
the motility of MCF7 and HepG2 cells, it reduced the motility of U373 MG 
cells. Furthermore, as a putative tumour suppressor, hepaCAM has two 
seemingly contradictory functions of inhibiting proliferation and yet 
increasing the motility of MCF7 and HepG2 cells, raising the possibility that 
its expression may be differentially regulated during tumourigenesis (Moh and 
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Shen, 2009). Hence, the use of xenograft models to profile tumour progression 
may help to shed light on these questions. 
Although it still remains to be elucidated how exactly the hepaCAM-mediated 
increase in GJIC in U373 MG cells contributes to tumour suppression, it may 
be useful to profile hepaCAM and connexin 43 expression in clinical samples 
at different stages of tumour progression to further understand the functional 
significance of their interaction. This may aid in the development of 
“bystander effect” therapeutic strategies (briefly discussed in section 1.7.3.2) 
that utilise GJIC to spread the effects of a therapeutic agent within a tumour 
mass. 
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CHAPTER 5 CONCLUSION 
HEPACAM is a putative tumour suppressor gene that is frequently 
downregulated in human HCC and other solid cancers. In this study, a novel 
interaction of hepaCAM with the gap junction protein connexin 43 in 
U373 MG glioblastoma cells is observed. Connexin 43, which has an aberrant 
intracellular localisation in U373 MG cells, is re-targeted to the plasma 
membrane at cellular junctions upon hepaCAM expression. In addition, 
hepaCAM expression leads to an increase in connexin 43 protein levels, not 
due to an increase in its transcription, but due to its enhanced stability from the 
interaction of these two proteins. The R92Q and R92W mutations in the 
hepaCAM extracellular domain, which are involved in the leukodystrophy 
MLC, weaken the interaction of hepaCAM with connexin 43 and fail to target 
connexin 43 to cellular junctions. This indicates that the interaction of 
hepaCAM with connexin 43 is important in the proper localisation of 
connexin 43 to cellular junctions in glioblastoma cells. 
The functions of hepaCAM in increasing adhesion, reducing migration and 
inhibiting proliferation do not appear to be dependent on its interaction with 
connexin 43. On the other hand, hepaCAM is observed to promote 
connexin 43-mediated gap junction transfer in U373 MG cells. Although the 
tumour suppressive properties of connexin 43 by GJIC-dependent mechanisms 
are not completely understood, we postulate that hepaCAM expression 
increases cell-cell contact and GJIC within a primary tumour, making it more 
difficult for tumour cells to detach and disseminate during metastasis. 
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The hepaCAM cytoplasmic domain undergoes proteolytic cleavage in MCF7, 
U373 MG and HepG2 cells, indicating that it may be a ubiquitous event in the 
processing of hepaCAM in different human cancer cell lines. Interestingly, 
cleavage of the cytoplasmic domain is inhibited by the R92Q and R92W 
mutations in the hepaCAM extracellular domain, as well as by the treatment 
with an antibody against the hepaCAM extracellular domain. We further show 
that upon integrin-mediated adhesion of U373 MG cells to fibronectin, 
hepaCAM undergoes endocytosis and is concomitantly cleaved. As the 
cleaved hepaCAM fragment can be found in the nucleus, it is likely that 
cleavage of the cytoplasmic domain has functions in regulating gene 
expression and mediating the tumour suppressive activities of hepaCAM. 
Further research needs to be done to identify the genes that are regulated by 
the cleaved hepaCAM fragment in order to expand our understanding of 
hepaCAM-mediated tumour suppression. 
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APPENDICES 





Supplementary Figure 1. Transfection efficiency of HEK293T cells. 
HEK293T cells were transfected with pEGFP-N2 using Turbofect 
Transfection Reagent. Cells were analysed by flow cytometry 48 h after 






Supplementary Figure 2. Optimisation of siRNA-mediated connexin 43 
knockdown in hepaCAM-expressing U373 MG cells. Wild-type hepaCAM-
expressing U373 MG cells were transfected with three different connexin 43 
siRNA duplexes from the GJA1 Trilencer-27 Human siRNA kit (OriGene) at 
two different concentrations, 1 nM or 10 nM. Untransfected cells and cells 
transfected with 10 nM universal scrambled siRNA were included as controls. 
Cells were lysed 48 h post-transfection, and 20 μg of cell lysates were 
subjected to western blot analysis using connexin 43 antibody. GAPDH was 
used as a loading control. Connexin 43 siRNA duplex C (SR301801C) was 
selected for subsequent experiments, as the knockdown efficiency was the 
highest. The concentration used was chosen as 5 nM, as the difference in the 
knockdown efficiency at 1 nM and 10 nM was slight. 




Supplementary Figure 3. Proteolytic cleavage of the hepaCAM 
cytoplasmic domain is inhibited by the antibody against the hepaCAM 
extracellular domain in both soluble and immobilised forms. MCF7 cells 
stably transfected with hepaCAM were treated with an antibody against 
hepaCAM extracellular domain (10 μg/ml) in immobilised or soluble forms. 
Mouse IgG (MOPC-21) was included as an isotype control. For the 
immobilised form, a 24-well plate was coated with the antibodies overnight at 
4°C, and rinsed with PBS twice before seeding of cells. For the soluble form, 
the antibodies were added directly to the cell culture media. Cells were seeded 
into the respective wells and incubated overnight with the antibodies. The next 
day, cells were lysed and 20 μg of cell lysates were subjected to Western blot 
analysis using anti-V5-HRP to detect the V5-tag on the hepaCAM 
cytoplasmic domain. GAPDH was used as a loading control. 
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APPENDIX II: BUFFERS AND REAGENTS 
 
Antibiotics stock solutions 
Antibiotics Concentration of stock solution 
Ampicillin 100 mg/ml in H2O 
Kanamycin 30 mg/ml in H2O 
Blasticidin 10 mg/ml in H2O 
Filter-sterilised through a 0.22 μm filter. 
 
10× PBS (1 L) 
Reagent Amount Final concentration 
NaCl 80 g 1.37 M 
KCl 2 g 27 mM 
Na2HPO4 14.4 g 100 mM 
KH2PO4 2.4 g 18 mM 
HCl Adjust to pH 7.4  
ddH2O Top up to 1 L  
 
1× PBS (1 L) 
Reagent Amount Final concentration 
NaCl 8 g 137 mM 
KCl 0.2 g 2.7 mM 
Na2HPO4 1.44 g 10 mM 
KH2PO4 0.24 g 1.8 mM 
HCl Adjust to pH 7.4  
ddH2O Top up to 1 L  
 
4% paraformaldehyde (100 ml) 
Reagent Amount Final concentration 
Paraformaldehyde 4 g 4% 
1× PBS 100 ml  
5 M NaOH Added dropwise till paraformaldehyde is fully 
dissolved 
HCl Adjust to pH 7.4  
Filtered through a 0.22 μm filter and stored at -20°C till use. 
 
0.1% crystal violet (100 ml) 
Reagent Amount Final concentration 
Crystal violet 0.1 g 0.1% 
Ethanol 20 ml 20% 
ddH2O 80 ml  
Filtered through a 0.22 μm filter to remove undissolved particulates. 
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PROTEIN LYSIS AND WESTERN BLOT REAGENTS 
 
RIPA buffer (250 ml) 
Reagent Amount Final concentration 
1 M Tris-HCl, pH 7.4 12.5 ml 50 mM 
NaCl 0.73 g 50 mM 
NP-40 2.5 ml 1% 
Sodium deoxycholate 0.625 g 0.25% 
10% SDS 2.5 ml 0.1% 
ddH2O Top up to 250 ml  
 
Non-denaturing lysis buffer for co-IP (50 ml) 
Reagent Amount Final concentration 
NP-40 0.5 ml 1% 
1× PBS 50 ml  
 
Resolving gel (10 ml) 
Reagent 10% gel 12% gel 
ddH2O 2.72 ml 2.05 ml 
1 M Tris-HCl, pH 8.8 3.75 ml 3.75 ml 
30% Acrylamide/bis solution, 29:1 3.33 ml 4.00 ml 
10% SDS 100 μl 100 μl 
10% Ammonium persulfate 100 μl 100 μl 
TEMED 4 μl 4 μl 
 
Stacking gel (4 ml) 
Reagent  
ddH2O 2.75 ml 
1 M Tris-HCl, pH 6.8 0.50 ml 
30% Acrylamide/bis solution, 29:1 0.67 ml 
10% SDS 40 μl 
10% Ammonium persulfate 40 μl 
TEMED 4 μl 
 
Towbin transfer buffer (1 L) 
Reagent Amount Final concentration 
Tris 3.03 g 25 mM 
Glycine 14.4 g 192 mM 
Ethanol 200 ml 20% 
ddH2O Top up to 1 L  
 
2× Laemmli sample buffer (50 ml) 
Reagent Amount Final concentration 
1 M Tris-HCl, pH 6.8 6.25 ml 125 mM 
Glycerol 10 ml 20% 
10% SDS 20 ml 4% 
β-mercaptoethanol 1.25 ml (added prior to use) 2.5% 
Bromophenol blue 5 mg 0.01% 
ddH2O 12.5 ml  
  160 
5× Laemmli sample buffer (40 ml) 
Reagent Amount Final concentration 
1 M Tris-HCl, pH 6.8 2.5 ml 62.5 mM 
Glycerol 4 ml 10% 
10% SDS 8 ml 2% 
β-mercaptoethanol 2 ml (added prior to use) 5% 
Bromophenol blue 4 mg 0.01% 
ddH2O 23.5 ml  
 
10× TBS (1 L) 
Reagent Amount Final concentration 
NaCl 88 g 1.5 M 
Tris base 24.2 g 200 mM 
HCl Adjust to pH 7.4  
ddH2O Top up to 1 L  
 
1× TBS (1 L) 
Reagent Amount Final concentration 
NaCl 8.8 g 150 mM 
Tris base 2.42 g 20 mM 
HCl Adjust to pH 7.4  
ddH2O Top up to 1 L  
 
TBST (1 L) 
Reagent Amount Final concentration 
1× TBS 1 L  
Tween-20 1 ml 0.1% 
 
Stripping buffer (1 L) 
Reagent Amount Final concentration 
Glycine 1.876 g 25 mM 
10% SDS 100 ml 1% 
HCl Adjust to pH 2.0  
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APPENDIX III: LIST OF PUBLICATIONS 
 
International Scientific Journals 
 
Wu MH, Moh MC, Schwarz H. hepaCAM associates with connexin 43 and 
enhances its localization in cellular junctions. (submitted). 
 
Selected Local and International Scientific Conferences 
 
Wu MH, Moh MC, Schwarz H. hepaCAM associates with connexin 43 and 
enhances its localization in cellular junctions. 6th Models of Physiology and 
Disease Symposium. Singapore, September 2014. (Poster Presentation). 
 
Wu MH, Moh MC, Schwarz H. hepaCAM associates with connexin 43 and 
enhances its localization in cellular junctions. Cell Symposia: Hallmarks of 
Cancer. Beijing, China, November 2014. (Poster Presentation). 
 
